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The platinum-base chemotherapeutic agent, oxaliplatin, is used to treat metastatic
colorectal cancer (CRC). Unfortunately, nearly all patients develop acquired resistance to
oxaliplatin after long-term use, limiting its therapeutic efficacy. Recent studies demonstrated
synergistic inhibition of colorectal tumor growth by the combination of cyclooxygenase-2
(COX-2) inhibitors with oxaliplatin. The major COX-2 product, prostaglandin E2 (PGE2), has
been implicated in colorectal carcinogenesis; however, it is unknown whether PGE2 affects
colorectal tumor response to oxaliplatin. In this study, we investigated the potential role of PGE2
in oxaliplatin resistance of human colon cancer cells. Total secreted PGE2 levels were
significantly increased in oxaliplatin-resistant HT29 cells (HT29 OXR) compared to parental
cells. This was associated with increased COX-2 (18-fold, 95% confidence interval [CI]=10.71
to 24.35, P=0.008) and reduced 15-PGDH levels (2.18-fold, 95% confidence interval [CI]=0.45
to 0.64, P<0.0001), indicating deregulated metabolic control of PGE2. Knockdown of
microsomal prostaglandin E synthase-1 (mPGES-1) sensitized HT29 OXR cells to oxaliplatin.
Selective inhibition of PGE2 receptor (EP4 receptor) by L-161,982 treatment demonstrated a
synergistic effect on oxaliplatin-induced cell apoptosis in OXR cells. L-161,982 also reduced the
expression of colonic stem cell markers (CD133 and CD44) expression and tumor sphere
formation by OXR cells. Furthermore, we identified that intracellular reactive oxygen species
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(ROS) accumulation, a key mechanism of oxaliplatin cytotoxicity, was significantly aggravated
by EP4 inhibition. Addition of the antioxidant N-acetyl cysteine (NAC) reversed cellular ROS
level in OXR cells and abolished the beneficial effect of EP4 blockade on oxaliplatin efficacy.

Overall, our findings uncover an important role for PGE2/EP4 signaling in
chemoresistance through regulation of oxidative stress and provide the rationale for targeting of
EP4 signaling for increased oxaliplatin efficacy in CRC patients.
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CHAPTER 1

INTRODUCTION

1.1

OVERVIEW OF COLORECTAL CANCER

1.1.1

Epidemiology of colorectal cancer
Colorectal Cancer (CRC), the cancer that develops in colon and rectum, is the third most

common cancer and the third leading cause of cancer death in United States. It is estimated that
in 2016, over 134,400 new cases of colorectal cancer will be diagnosed, while about 49,190
Americans will die from colorectal cancer, accounting for 8% of all cancer deaths(1). In United
States and worldwide, the incidence and mortality of CRC in women and men is equal; the
lifetime probability of developing CRC is 5.56% (1 in 18 ) for women and 5.88% (1 in 17) for
men (2,3) .

The risk of developing colorectal cancer increases with age; about 70% CRC cases occur
in those aged 65 or older. This is partially due to the slow progression from precancerous polyp
to metastatic CRC, which usually takes 10 to 20 years (4) . Taking advantage of the slow course
of CRC development, colonoscopy screening among individuals over the age of 50 helps in early
diagnoses and precancerous lesion removal, which results to CRC incidence decline by 3%
annually in the past decade(2). However, the high incidence and death number has made CRC a
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severe problem for public health; research efforts are needed in understanding CRC pathology
and developing effective therapeutic strategies to increase the overall survival rates of CRC
patients.

1.1.2

Risk factors
According to the epidemiological studies, the lifetime risk of colorectal cancer for an

average US citizen (man or woman) is approximately 5% (5) . Besides age, there are many other
factors that are known to increase the risk of developing CRC. These risk factors could largely
fall into two categories: non-modifiable factors and modifiable factors. Non-modifiable factors
include family history, which is associated with incidence of inherited colorectal cancers, and
medical conditions such as Inflammatory Bowel Disease (IBD). Modifiable factors include
dietary factors, lifestyle factors (behavior factors) and environmental factors. Evidence from
published literatures has suggested that some risk factors are significantly associated with
increased colon cancer risk (6) . On the other hand, several factors such as effective health care
for medical conditions and healthy lifestyle are found to be inversely associated with CRC risk,
indicating possible preventive strategies.

Among all the CRC cases, up to one-third of colon cancers demonstrate increased
familial risk, indicating the possible significance of inheritance in risk of developing colon
cancer (7) . According to 16 epidemiologic studies based on 8,091 cases of CRC, the risk of
CRC for individuals with family history (first-degree relatives) of CRC is significantly higher
compared to those with no family history of colon cancer (p=0.001; RR [rate ratio]=1.80, 95%CI
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[confidence interval]=1.61-2.02). The pooled analysis of these studies didn’t show statistical
significant difference base on genders or study design (6) .

Besides the undefined inherited forms of colon cancer, it is known that approximately 5%
of CRC cases are associated with well-defined inherited syndromes, including familial
adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC, or
Lynch syndrome). FAP is the best-characterized inherited CRC syndrome. FAP syndrome is a
autosomal-dominant genetic disorder, its unique feature is the appearance of hundreds even
thousands colonic adenomas in affected individuals starting from early adolescence. The risk of
colon cancer for classic FAP patient is 100% without treatment. The average age of CRC
diagnosis in FAP patients is 39, while 95% of those cases are diagnosed before age 50 (7) . Even
for attenuated patients who exhibit a less severe form of FAP, the average lifetime risk of CRC is
as high as 69%. Both classic FAP and attenuated FAP are caused by germline mutations in APC,
which is an important tumor suppressor gene located in chromosome 5q21. The APC gene is part
of the WNT signaling pathway in GI epithelial cells, and regulates cell growth through inhibiting
β-catenin-induced cell proliferation (8) . When the APC gene is silenced/truncated via inherited
or de novo mutations, cells lose the “gatekeeper” and start proliferating rapidly, resulting to
increased possibilities of more genetic mutations and malignant transformation, leading to the
development of numerous colonic polyps and eventually colorectal cancer.

Another well-known CRC-associated inherited syndrome is HNPCC, also called Lynch
syndrome. Lynch syndrome accounts for about 2%-4% of all CRC cases. Although it is rare to
observe polyposis in Lynch syndrome patients (distinct from FAP), the affected individuals do
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develop colonic adenomas at younger age and bear a significantly higher lifetime risk (50%80%) of CRC compared to the general population (9) . Lynch syndrome results from germline
mutations in a group of genes related to DNA mismatch repair (MMR), including hMSH2,
hMLH1, and hMSH6. As the MMR system is crucial for maintaining genomic stability by
correcting mismatches during DNA replication in S phase of cell cycle, the defects in MMR
genes lead to high-level of microsatellite instability (MSI-H), which induces the malignant
transformation of epithelial cells. Besides colon cancer, Lynch syndrome is also highly
associated with other types of cancers, including endometrial cancer, gastric cancer and ovarian
cancer (10) .

Besides the heritable cancer syndromes, another medical condition called IBD has also
been shown to be significantly associated with increased risk of CRC. The two main forms of
IBD are Crohn’s disease and ulcerative colitis. In a cohort study of 5529 patients with IBD (2857
patients had Crohn’s disease and 2672 had ulcerative colitis), the incidence of CRC in IBD
patient was significantly higher compared to the non-IBD population (IRR [incident rate
ratio]=2.64 for Crohn’s disease and IRR=2.75 for ulcerative colitis, respectively) (11) . The risk
of CRC has been shown positively related to the duration and anatomic extent of IBD, and the
proper health care such as usage of non-steroidal anti-inflammatory drugs (NSAIDs) was
associated with decreased risk of developing CRC compared to non-treated IBD patients (12) .

Other than the non-modifiable factors, several lifestyle factors, including diet and
behaviors, have also been suggested as risk factors for CRC. For example, population-based
studies have shown an overall significant positive correlation between risk of colon cancer and
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high consumption of red meats, such beef and pork (13) . In contrast, consumption of fruits and
vegetables is found to be inversely correlated with CRC risk (6) . On the other hand, certain
behaviors could become CRC risk factors as well. Cigarette smoking has been confirmed as
significant causative factor for lung cancer (14) . Studies have shown that long-term heavy
smokers of cigarettes, especially those who have used tobacco for more than 30 years, are also at
a significant higher risk for developing colorectal cancer, compared to a non-smoking population
(15) . Heavy consumption of alcohol was also associated with higher risk of CRC development
(RR=1.26 per 20drinks/week), but no statistical significance was found (6) .

Overall, large population-based studies have revealed several significant risk factors for
CRC development in an individual’s lifetime. The discovery of modifiable factors suggests
several primary preventive strategies, such as reducing red meat consumption and maintaining a
healthy lifestyle. On the other hand, the studies on non-modifiable factor such as genetic
alterations and IBD provide potential targets for secondary prevention and clinical management
of colorectal cancer, which will be discussed in the following sections.

1.2

PATHOGENESIS OF COLORECTAL CANCER

1.2.1

Staging of colorectal cancer
The large intestine is an important part of the digestive (gastrointestinal) system in human

body. While the stomach and small intestine are critical for food digestion and most nutrient
absorption, colon and rectum are responsible for absorbing water and mineral nutrient, as well as
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get rid of the waste. The colon and rectum have complex physiological structures, consisting of
four layers from the lumen towards the abdominal cavity: the mucosa, the submucosa,
muscularis propria (muscle layer) and serosa. Mucosa is the innermost lining made of epithelial
cells and glands (also referred to as crypts), secreting mucus and absorbing nutrients. Its is
surrounded by submucosa, where the blood vessels, nerves and connective tissue form a layer to
transfer the nutrient and support the mucosa function. The muscularis proporia contains layers of
smooth muscle to help food process through the intestine, and the serosa is the outermost layer as
a barrier between the large intestine and other vital organs in abdominal organs. The large
intestine is also supported by lymphatic system through nearby lymph nodes. Multiple types of
immune cells are located through the colonic layers and help maintain the GI homeostasis.

It is known that the almost all colorectal cancers start from the noncancerous abnormal
growth (also referred to as “polyp”) of epithelial cells within the mucosa layer of colon or
rectum. Once the benign to malignant transformation take place, the cancer cells will keep
proliferating and acquire invasiveness, leading to continuous growth of tumor through the colon
wall, even penetration into the blood or lymphatic system, therefore forming local or distant
tumors in organs or lymph nodes (16) . In clinical settings, to assess the prognosis of colorectal
cancer and determine the choice of treatment respectively, the American Joint Committee on
Cancer (AJCC) has designated the staging of colorectal cancer based on the TNM system
(T=primary tumor; N=regional lymph nodes; M=distant metastasis) (17) . According to the
pathology and affected areas, five stages are divided and the standard treatment varies between
different stages (Figure 1). In stage 0 (Carcinoma in situ), abnormal growth of colonic epithelial
cells form precancerous lesions or cancer (polyps) within the mucosa of colon. These polyps can
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be removed surgically via local excision or resection. In localized stages (stage I & II), the
primary tumor spreads across multiple layers but is still restricted within colon wall, so surgical
resection of colon segment is the standard treatment. In stage III (regional stage), cancer has
penetrated the colon wall and spread to the nearby lymph nodes or tissues. Treatment options
include surgical removal (resection) followed by chemotherapy, to avoid tumor recurrence. As
for stage IV cancer (distant stage), when cancer has spread to distant lymph nodes or form
metastasis in distant organs such as liver, lung or ovary, or recurrent tumors, surgical removal of
the affected organs is required. Chemotherapy may be given before or after surgery. Radiation
therapy and targeted therapy may be used to improve the survival or relieve symptom of patients.

Besides the staging, another key feature of colorectal cancer is the location of tumors.
There are four sections of colon: the ascending colon, which connects with small intestine; the
transverse colon which cross the abdomen from left to right; the descending colon; and the
sigmoid colon which connects the rectum. Clinically, the ascending and transverse colon are
referred to as proximal colon, while the descending and sigmoid colon together are referred to as
distal colon. Studies have shown that colorectal tumors located at different locations within the
large intestine have very different morphology, histology and epidemiological features (18) . For
example, colorectal tumors located with proximal colon tend to have higher prevalence in female
and older population and usually exhibit “serrated”, mucinous histological features (19) . These
characteristics are significantly associated with different molecular pathways involved in
colorectal carcinogenesis, which will be discussed in details in the following section.
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Adapted from Advances in colorectal cancer research [Internet].
National Institute of Health, Bethesda, MD.
Available from https://www.nih.gov/research-training/advances-colorectal-cancer-research

Figure 1. Staging of colorectal cancer.
Stage 0 (Carcinoma in situ), abnormal colonic cells form precancerous lesions or cancer in
mucosa.
Stage I, cancer is formed in mucosa (innermost layer) and submucosa, but still restricted within
the colon wall.
Stage II (localized stage), the primary tumor spreads through the colon wall, might have spread
through the serosa (outermost layer) and reach nearby organs.
Stage III (invasive stage), cancer has spread through the colon serosa and reach up to 7 nearby
lymph nodes or nearby tissues.
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Stage IV (distant stage), primary tumor has spread through colon wall and reached nearby lymph
nodes and organs. Cancer cells may also migrate through blood/lymph system and form tumor
metastasis in distant lymph nodes or organs, such as liver, lung or ovary.

9

1.2.2

Genetic and epigenetic alterations in CRC carcinogenesis
It has been shown that during colorectal tumor development, certain gene mutations and

epigenetic changes take place in epithelial cancer cells. These alterations lead to dyregulation of
several molecular pathways, which are key regulators of cell proliferation and survival, therefore
play as driving forces in almost every aspect of colon cancer, including initiation, progression,
invasion, metastasis and angiogenesis (20) . In this section, these genetic and epigenetic
alterations, their associated molecular pathways in CRC carcinogenesis and their implications for
CRC prognosis are discussed.

As mentioned in last section, germline mutations in the APC gene are responsible for the
FAP syndrome. APC is an important component of the WNT/APC/β-catenin/Tcf complex,
dysregulation of which is an early step in the classical adenoma-carcinoma pathway of CRC. The
WNT pathway plays an important role in the regulation of both the embryonic development and
the adult tissue self-renewal (21) . Under normal conditions, the APC/Axin/GSK-3β complex
binds to β-catenin and triggers its phosphorylation, which leads to its further degradation. When
Wnt ligands bind to the Frizzled receptor complex, downstream signaling leads to inactivation of
the APC/Axin/GSK-3β complex, thereby releasing β-catenin and enabling its translocation to
nucleus. This further activates the transcription factor, Tcf, and the Tcf-target genes, regulating
multiple biological events, including proliferation and differentiation (22) . However, in
colorectal cells from FAP patients or some sporadic CRC patients, the mutations in APC reduce
the formation of the APC/Axin/GSK-3β complex, which results in constitutive activation of βcatenin and Tcf, therefore leading to uncontrolled proliferation, differentiation and even
migration of cells, initiating colon carcinogenesis. Besides mutations in APC, other somatic gene
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mutations are also involved in hyper-activation of the WNT pathway, including the mutations in
β-catenin itself (present in about 48% colorectal tumors without APC mutations) and its
regulators in the Notch pathway (23,24) . Another important oncogene involved in β-catenin
regulation is cyclin dependent kinase-8 (CDK8), which is activated in approximately 60% of
CRC cases (22) . The studies by Firestein and colleagues showed that CDK8 kinase activity is
required for β-catenin-driven malignant transformation in colon cancer cells, and the
overexpression of CDK8 is significantly correlated with colon cancer mortality (p=0.039; HR
[harzard ratio]=1.70; 95%CI=1.03-2.83) (25,26) .

Although the early mutations in the WNT pathway initiate the transformation process of
colon epithelial cells, subsequent mutations in other pathways are required for the benign to
malignant transformations. Mitogen-activated protein kinases (MAPK) pathway, an important
pathway that controls normal cell growth and survival, is confirmed to be involved in colorectal
carcinogenesis (Figure 2). The mutations in its key components, the RAS and RAF oncogenes,
are observed in approximately 60% of all colon cancer cases, indicating the importance of the
MAPK pathway in CRC (27) . To initiate MAPK signaling, secreted growth factor ligands, such
as epidermal growth factor (EGF) bind to the receptor tyrosine kinase (RTK) on the cell surface
membrane. Upon the binding, RTKs get phosphorylated and activated, further binding the son of
sevenless (SOS) complex. The SOS complex binds to its downstream guanosine diphosphate
(GDP)-RAS protein, and facilitates the switch from GDP to guanosine triphosphate (GTP),
therefore activating RAS. GTP-RAS recruits and activates the RAF proteins, which in turn
activate the downstream MEK and ERK. Activated ERK enters cell nucleus and further activate
the transcript factors including Jun and Fos, which bind to AP-1 and activate the transcription of
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their target gene, promoting cell proliferation (28) . In normal cells, the activation of MAPK
pathway is tightly regulated by RAS-GTPase activating (GAP) protein, which switch GTP to
GDP and inactivate RAS. However, during carcinogenesis, mutations in RAS proteins, most
commonly in KRAS, lead to constitutive RAS activation and enable the cells to keep proliferating
and escape apoptosis, promoting the adenoma-carcinoma transition (29) . This step is frequently
followed by other genetic changes such as p53 loss of function, to stimulate vigorous
proliferation of cancer cells during later stage of colorectal tumorigenesis (30) . On the other
hand, KRAS mutations are also shown to promote tumor invasion and metastasis in mouse
models, whereas suppression of KRAS reduces its pro-tumorigenic functions, suggesting that
KRAS could be a potential therapeutic target for advanced CRC (31) .

In contrast with the significance of RAS mutations in the classic pathway of CRC,
another important component of MAPK pathway, BRAF, has been implicated as key player in
the development of a distinct subtype of CRC via the “serrated” pathway (32) . Oncogenic BRAF
mutations, most commonly V600E mutation, appear in approximately 10% CRC cases and are
mutually exclusive with KRAS mutations (33) . These BRAF mutated colorectal tumors are
primarily located in the proximal (right side) colon and exhibit distinct features including
mucinous histology, serrated polyps/adenoma and poorer differentiated tumor mass (34,35) .
Studies also showed that these tumors are highly methylated compared to the BRAF-wild type
ones, thus characterized as CpG island methylator phenotype (CIMP)-high tumors. In contrast,
the KRAS mutated cancers are usually associated with low level of DNA methylation (CIMPlow). Also, the BRAF mutant tumors are significantly correlated with MSI (36) . The studies by
Kang group (37) and Thibodeau group (38) showed that the BRAFV600E mutations are strongly
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associated with hyper-methylation of hMLH1 promoter rather than hMLH1 germline mutation,
while the KRAS mutations are associated with hMLH1 un-methylated tumors. Methylation of
hMLH1 promoter leads to silencing of hMLH1 and defective DNA mismatch repair. These
studies suggest that BRAF-mutated serrated polyps/adenoma might be the precursor of hMLH1methylated colorectal cancer.

Epidemiological studies showed that compared to BRAF-wild type CRC, BRAF-mutated
colorectal cancer demonstrate significant prevalence in female (95% vs 44%, p<0.001) and in
patients with advanced age (average age 75 vs 66, p=0.004) (36) . BRAF mutant cancers are also
associated with worse prognosis for different stages of CRC, with significantly lower 5-year
survival (47.5% vs 60.7%, p<0.01), regardless of microsatellite stability or mismatch repair
proficiency (39,40) . These studies suggest BRAF mutation as negative prognostic factor for
colorectal cancer. On the other hand, significance of BRAF in CRC has been well appreciated,
which elicits extensive studies on development of strategies targeting mutated BRAF (such as
vemurafenib, the first FDA-approved BRAFV600E inhibitor) for CRC therapy.

Another important pathway in colorectal carcinogenesis is phosphoinostide-3 kinase
(PI3K) pathway (Figure 2). Same as the MAPK pathway, activation of the PI3K pathway starts
with growth factors binding to RTKs. Activated RTKs binds to PI3K complex and activate its
catalytic subunit, p110. P110 phosphorylates phosphatidylinositol biphosphate (PIP2) to PIP3,
and the latter recruits Protein kinase B (PKB, or AKT). Once AKT is phosphorylated and
activated by PIP3, it binds to the downstream signaling factors such as Nuclear Factor-κB (NFκB) or Bcl-2 family proteins, promoting cell metabolism and survival (41) . In normal cells, the
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PI3K pathway is tightly regulated by the tumor suppressor gene phosphatase and tensin homolog
(PTEN), which dephosphorylates PIP3 to inhibit AKT phosphorylation. However, in cancer
cells, oncogenic mutations in PIK3CA (the gene encodes p110) or nonsense mutations in PTEN
will lead to constitutive activation of AKT, therefore promote cancer cell proliferation, survival
and invasiveness. Mutations in PI3K pathway are observed in 15%-25% of CRC cases and often
occur simultaneously with APC alterations, resulting to synergistic effects in colorectal
carcinogenesis (42) . Interestingly, RAS could activate PI3K pathway by directly binding to
normal p110. The mutant RAS could bind PIK3CA mutated p110 effectively in cancer cells,
suggesting the crosstalk between MAPK and PI3K pathways during colorectal carcinogenesis
(43) .

Besides gene mutations and methylations other genetic factors have also been found to
play important roles in colorectal carcinogenesis. MicroRNAs (miRNA), originally discovered in
C. elegans, are small (length of 20-22 nucleotides) non-coding RNA molecules found in most
eukaryotes including plants, animals and humans (44) . MiRNAs account for up to 5% human
genome and regulate the expression of at least 30% of protein coding genes, particularly genes
involved in cell proliferation and differentiation, therefore play important roles in both healthy
tissues and cancer (45,46) . For example, studies by James and colleagues demonstrated the
reduction of miRNA-143 and miRNA-145 expression in precancerous colonic polyps, compared
to normal mucosa, suggesting miRNAs are involved in CRC neoplasia (47) . Altered expression
of miRNAs have also been found in colorectal cancer tissues, with distinct expression pattern in
accordance with mutations in KRAS and BRAF (mutually exclusive), suggesting that dyregulated
miRNA expression is associated with RAS-RAF signaling in human colon cancer (48) .
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Additionally, expression of several miRNAs including miR-18a, miR-21 and miR-203 have been
shown correlated with worse prognosis of advanced CRC patients (49,50) , suggesting that the
emerging studies on miRNAs could provide potential predictive biomarkers even therapeutic
targets to achieve better clinical outcomes.

Overall, a better understanding of the molecular changes and their associated signaling
pathways involved in CRC will help to develop novel therapeutic strategies that may improve
clinical outcome. The discovery of multiple biomarkers will help develop effective CRC
preventive strategies for high-risk populations and give better predictions of prognosis for CRC
patients. More importantly, analysis of the genetic and epigenetic profile of a specific patient will
help define the most effective targets and aid in the development of individualized treatment
approaches, therefore improving the overall survival of CRC patients.

15

Adapted from Clarke and Kopetz, Journal of Gastrointestinal Oncology, 2015

Figure 2. MAPK pathway and PI3K pathway. Epidermal growth factor (EGF) binds to its
EGFR receptor (RTK) and activates downstream RAS-RAF signaling as well as PI3K-AKT
signaling, promoting expression of genes involved in cell growth and proliferation. Mutations in
RAS, RAF or PI3K leads to constitutive activation of these signaling cascades, resulting in
uncontrolled proliferation of affected cells, promoting tumor growth.
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1.2.3

Tumor microenvironment and cancer-associated fibroblasts
Besides the malignant transformation in cancer cells, recent studies have also

demonstrated the significance of the tumor-stromal interactions during tumorigenesis in different
types of cancer, implying that the tumor microenvironment is not just a benign bystander, but
actually an important modulator and even key player in tumorigenicity (51) .

In solid tumors, the tumor microenvironment mainly consists of tumor-infiltrating stroma
cells, extracellular matrix (ECM) and other non-cellular components. Stromal cells are
considered to represent a highly heterogeneous group of different cell type, including fibroblasts,
adipocytes, endothelial cells, immune cells and mesenchymal stem cells (MSCs) (52-55) .
Although each type of cells maintains distinct properties and functions, the pro-tumorigenic,
typically inflamed tumor microenvironment is represented by the coordinated contributions from
each cell type via extensive intercellular cross talk (56) .

An important group of cells within tumor-associated stroma are referred to as cancerassociated fibroblasts (CAFs). CAFs are comprised of activated fibroblasts originating from a
diverse group of cell types, including resident fibroblasts (57) , bone marrow-derived
mesenchymal stem cells (58) , adipocytes (59) , endothelial cells (60) and even under certain
circumstances the neighboring epithelial cells (61,62) . During the development of primary and
metastatic colorectal cancer, upon the interactions between stroma and epithelial-derived cancer
cells, normal resident fibroblasts (NRFs) get activated and further acquire a new set of
properties; these CAF properties include robust proliferation, enhanced migratory capacity, upregulation of pro-inflammatory signaling, and increased secretion of cytokines or growth factors
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(63) . Although there is no CAF-specific biomarker, CAFs express myofibroblast markers αsmooth muscle actin (α-SMA) and fibroblast activation protein (FAP) (64-66) . In several recent
clinical studies, a strong association has been demonstrated between elevated levels of CAFs and
poor prognosis in patients harboring colorectal tumors (67,68) . High levels of stromal FAP
expression have also been considered as an indicator of aggressive tumor behavior, including
metastases and recurrence of different malignancies (67,69,70) . These findings suggest that
CAFs may be important players during cancer progression, provoking strong interest in
understanding their functions during tumor growth and metastasis.

CAFs have been shown to produce various cytokines and growth factors, including IL-6,
hepatocyte growth factor (HGF) and insulin-like growth factor (IGF) during colorectal cancer
growth (71-74) , to promote cancer cell proliferation and migration. Furthermore, IL-6 can
stimulate the expression of vascular endothelial growth factor (VEGF) by CAF in an autocrine
manner, promoting the angiogenesis in tumor mass (74) . Interestingly, many growth factors and
cytokines are also produced by cancer cells and stimulate the proliferation of CAFs. This
crosstalk forms positive feedback loops between tumor and stromal cells, further promoting
tumor progression. Recently, several studies have been done to target the crosstalk between
cancer cells and CAFs for their anti-cancer therapeutic potential. Cheng and colleagues (75)
found that interfering with tumor-stromal interactions could significantly reduced tumor growth
in the azoxymethane-dextran sulfate sodium (AOM-DSS) mouse model. A recent study by Li et
al. (76) demonstrated that inhibition of CAFs by targeting FAP activity significantly suppressed
tumor growth and angiogenesis in a xenograft mouse model. Interestingly, they also discovered
that suppression of CAF synergistically enhanced the efficacy of oxaliplatin. Consistent with
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these findings, several related studies have also demonstrated that tumor-associated fibroblasts
are involved in resistance to chemotherapeutic treatments (e.g. oxaliplatin) through restoring a
cancer stem cell phenotype in colorectal cancer (72,77) .

Overall, these findings indicate the significance of tumor-microenvironment, especially
cancer-associated fibroblast, in colorectal cancer progression. In addition, it is also suggested
that CAFs may be a potent target in CRC prevention and therapy. The current preventive and
therapeutic strategies for CRC, and the latest findings will be discussed in the following sections.

1.3

PREVENTION OF COLORECTAL CANCER

1.3.1

Conventional prevention strategies
Given the slow carcinogenesis and multi-stage progression, colorectal cancer is among

the malignancies that could benefit from prevention, and effective preventive strategies have
been shown to reduce both the incidence and the mortality of CRC (78) . As previously
mentioned, almost two-thirds of the total CRC cases are sporadic and are related with modifiable
risk factors such as diet and behavior factors (smoking, alcohol and red meat consumption, etc.),
suggesting that effective interventions on modifiable factors could possibly reduce the incidence
of CRC in average-risk population (free of family CRC history and CRC symptoms). These
feasible interventions (also known as health promotion programs) are regarded as primary
preventive strategies, which include reducing alcohol consumption and smoking frequency,
keeping a diet high in fruits and vegetables while low in red meat, doing regular physical
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exercises, etc. It is estimated that approximately 66% of CRC cases are preventable by changing
diet and maintaining healthy lifestyle (79) . However, changing diet and lifestyle are effective at
long-term CRC prevention and it must be accompanied by preventive strategies with short-term
impact, such as CRC screening.

It is well known that the prognosis of CRC is highly associated with the stage at
diagnosis (80) , early detection and treatment provide significant advantage in improving the
survival rate of CRC patients. Therefore, different from the primary prevention, which provides
general protection for healthy individuals from getting CRC, the secondary preventive strategies
(CRC screening) actually aim to detect and remove precancerous lesions or even early-stage
CRC, and exhibit immediate impact on reducing the incidence and mortality of CRC. There are
mainly two types of screening, visualization of large intestine (colonoscopy) and analysis of
biological samples (fecal occult blood test, FOBT). Currently, since the risk of CRC increases
with age, it is recommended that individuals with average risk (asymptomatic, no risk factors)
start population-based screening at age 50. For people with increased risk for CRC, including
family/personal history of CRC and personal history of IBD, the screening is suggested to start
from age 40 or earlier with short intervals between each screening.

There are several screening methods to visualize the large intestine, including
colonoscopy, sigmoidoscopy and CT colonography. Colonoscopy is regarded as the gold
standard for CRC diagnosis, and has been shown to significantly reduce the incidence (67%
reduction) and mortality (65% reduction) of CRC in several clinical studies (81,82) .
Colonoscopy also exhibits better sensitivity and specificity for smaller (6mm~10mm) colonic

20

lesions than CT colonography (98% vs. 63%) (83) . Moreover, compared to sigmodioscopy,
which is only effective on distal colon neoplasm detection, colonoscopy demonstrates better
coverage. However, studies have shown that the beneficial effect of colonoscopy on CRC
prognosis is strongly associated with the location of CRC (distal colon favorable that proximal)
and the specialty of the endoscopist (84) . Colonoscopy also has other disadvantages including
cost, lower acceptance and complications due to the invasive nature of the test, which limit the
its application.

On the other hand, analyses of biological samples (feces, plasma and urine) have become
more accepted population-based screening strategies. These methods include FOBT,
fecal/plasma DNA and RNA test, and protein test. Since most cases of CRC tend to bleed during
the early stages of tumor development, testing the occult blood in the stool (fecal hemoglobin)
has been proved as an effective method for detecting the colonic neoplasia in several clinical
studies, with sensitivity ranged approximately from 62% to 80% and specificity ranged from
65% to 98%, depending on whether its guaiac based (gFOBT) or immunological based (FIT)
(85) . In fact, due to its low cost and non-invasive nature, FOBT has become the most used
population-based screening method for CRC in Europe and worldwide. However, since the tests
used in gFOBT are not specific for human hemoglobin, patients are recommended to restrict red
meat consumption to avoid false positive and colonoscopy are to be performed on patients with
positive FOBT results (86) .

On the other hand, as discussed in previous sections, CRC carcinogenesis is associated
with multiple genetic and epigenetic alterations. Besides the genetic mutations in APC and MMR
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genes, which are the key features for high-risk population, several other genetic and epigenetic
markers in biological samples have been developed as diagnostic strategies for detecting colonic
neoplasia in average-risk individuals (87) . So far, fecal and plasma marker panels include gene
mutations in APC, KRAS, p53 and genes involved in EMTs; methylations in such gene promoters
and RNA expression levels of genes such as COX-2 have also been tested for CRC diagnosis
(88,89) . A recent study by Link and colleagues also suggested that abnormal levels of fecal
miRNAs such as miR-21 and miR-106a could be used as biomarkers for colonic neoplasia
screening with specificity of approximately 75% in average-risk population (90) . Although the
DNA/RNA tests have higher cost and need improvement in specificities, analyses of genetic and
epigenetic biomarkers have exhibited remarkable accuracy and better coverage for diagnosis of
early lesions than conventional methods (91) . More studies are required for development of
biomarker panels to achieve better specificity and lower cost for CRC early diagnosis.

1.3.2

Aberrant Crypt Foci as surrogate biomarkers for colon cancer
Colorectal carcinogenesis is known to arise from pre-neoplastic lesions comprised of

abnormal epithelial cells. Although the conventional CRC pathway is regarded as “polypadenoma-carcinoma” pathway, recent studies suggested that aberrant crypt foci (ACF), described
as the cluster of colonic crypts morphologically different from normal surrounding mucosa, is in
fact the earliest neoplastic lesion in CRC progression and might be a surrogate biomarker for
clinical CRC prevention.

ACF was first discovered in AOM mouse model by Bird in 1987 using methylene blue
staining (92) , and has intrigued many related pre-clinical and clinical studies ever since. Similar
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as methods used in animal studies, human ACF could be detected in high-magnification
chromoscopic colonoscopy (HMCC) through staining. Compared to regular endoscopic
technologies, HMCC has higher magnification and sensitivity for flat or depressed lesions, and is
widely used in clinical settings to reduce the false-negative rate of CRC screening (93) . In
HMCC, ACFs stand out from the background as elevated, usually deeper stained cluster of larger
crypts with abnormal shape, and can be removed by endoscopic biopsy for further histological
and molecular analysis (94) .

Based on histological features, almost all ACFs can be classified into two main subtypes:
hyperplastic ACF and dysplastic ACF. Hyperplastic ACFs are characterized as larger and longer
crypts (compared to normal ones) with abnormal, sometimes serrated luminal openings. Similar
as hyperplastic polyps, the hyperplastic ACFs exhibit hyper-proliferation of epithelial cells,
represented by upward expansion of positive staining for proliferating cell nuclear antigen
(PCNA) and Ki-67 protein in abnormal crypts (95) . On the other hand, dysplastic ACFs may not
be larger than normal crypts or having serrated features, but demonstrate histologic features of
dysplasia, including nuclei elongation, stratification, or polymorphism in epithelial cells, and
positive staining of PCNA and Ki-67 in upper crypts (96) . Similar as adenomas or colorectal
cancers with distinct histological characters, different ACFs result from correlated molecular
features and have been implied as precursors for different CRC progression pathways.

Multiple studies have shown that ACFs share similar molecular features, including
genetic and epigenetic alterations with CRC, providing strong support for their role as preneoplastic lesions for CRC. For example, alterations in WNT pathway such as APC mutations
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and β–catenin nuclear expression, have been found in both ACFs and CRC. Interestingly, in
sporadic APC mutations and β–catenin nuclear translocation are more likely to be found in
dysplastic ACFs, while KRAS mutations occur more frequently in hyperplastic ACFs (97) . In
FAP patients who carry germline mutations in APC, the prevalence of dysplastic ACFs is
significantly higher than hyperplastic ACFs (98) . On the other hand, the serrated hyperplastic
ACFs often carry oncogenic mutations of KRAS or BRAF (mutually exclusive), correlated with
DNA hyper-methylation (CIMP), suggesting that hyperplastic ACFs may be the precursor
lesions of the serrated CRC pathway (99) . Moreover, the level of microsatellite instability (MSI)
has been shown gradually increasing in ACFs to adenoma and carcinoma, compared to the
normal colonic mucosa (100) , suggesting ACFs could be early precursors in Lynch syndrome
associated colorectal cancers. Moreover, a recent study by our lab deciphered the cellular
interplay between ACF and adjacent normal-appearing stroma in CRC patients, highlighting the
activation in NF-κB pathway and stromal fibroblasts, suggesting that ACF, as the earliest preneoplastic lesion in colorectal carcinogenesis, is associated with inflammation and altered
stromal microenvironment (101) .

Overall, clinical and pre-clinical studies have indicated ACFs as the pre-neoplastic
lesions of CRC and potential biomarker for CRC prevention. Further studies such as more
complete characterization of genomic profile of ACFs, better understanding of molecular
pathways involved in CRC carcinogenesis, especially the crosstalk between neoplastic lesions
and stromal microenvironment are required for promoting the clinical application of ACF as
surrogate marker for CRC.
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1.3.3

Prostaglandin E2 (PGE2) and colorectal cancer prevention
Besides the population-based CRC screening through colonoscopy, developing effective

chemo-preventive strategies to reduce CRC incidence in high-risk population is another
promising field. Since the 1980s, studies have shown that regular use of non-sterodial antiinflammatory drugs (NSAIDs) such as aspirin, sulindac, and ibuprofen is associated with
significantly reduced risk of CRC (102-104) . Recent clinical trials indicated the long-term (5
years or longer) low-dose (75mg or less daily) use of aspirin significantly reduce colorectal
cancer incidence (~30%) and mortality (~40%) (105) . The effect of NSAIDs on CRC prevention
is believed to be largely attributed to their suppression of pro-inflammatory prostaglandin
synthesis by cyclooxygenase (COX) enzyme inhibition (102) . COX inhibition leads to less
synthesis of down-stream prostanoids, including prostaglandin (PG) D2, PGE2, PGF2α,
prostacyclin (PGI2) and thromboxane A2 (TXA2) (Figure 3). These lipids are critical in various
physiological processes (i.e. inflammation, platelet aggregation, wound healing) and PGE2 is
known as the most important bioactive lipid in the human body, particularly with respect to its
effects on inflammation and tumorigenesis (106) .

PGE2 has been shown to regulate various physiological and pathological events. Within
the digestive system, PGE2 helps to maintain mucosal integrity and maintain GI track
homeostasis (107) . During acute or chronic inflammation, PGE2 promotes early inflammatory
response by facilitating immune cells infiltration and also resolute inflammation by regulating
cytokines and chemokine expression (i.e. IL-2, CCL19) (108) . Normally PGE2 synthesis is
tightly regulated through modulation of the expression or activity of its synthases (COX enzymes
and PGE2 terminal synthases). However, during colorectal tumorigenesis or chronic
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inflammation the levels of PGE2 are significantly elevated within the colonic mucosa (109) , due
in part to the coordinated up-regulation of COX-2 and mPGES-1, an effect that is caused by
growth factors and/or inflammatory stimuli such as LPS (106) .

26

Figure 3. PGE2 synthesis pathway. Arachdonic acid is released from membrane phospholipids
by calcium-dependent phospholipase A2 (cPLA2), and gets rapidly oxidized to unstable PGG2,
then reduced to PGH2. Both steps are catalyzed by COX enzymes (COX-1 and COX-2). PGH2 is
subsequently converted to PGE2 or other prostanoids, including prostaglandin (PG) D2, PGF2α,
prostacyclin (PGI2) and thromboxane A2 (TXA2). The three specific terminal synthases for PGE2
generation are microsomal PGE synthase 1(mPGES-1), mPGES-2, and cytosolic PGE synthase
(cPGES). NSAIDs inhibit the activities of COX enzymes and suppress the synthesis of
prostaglandins.
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Besides the up-regulation of PGE2 levels in CRC patients, other studies have shown that
PGE2 may promote colorectal tumorigenesis directly in vitro and in vivo. In multiple CRC mouse
models, it is shown that administration of exogenous PGE2 or a PGE2 analogue increases the
incidence and multiplicity of intestinal tumors (110,111) , while PGE2 suppression through
genetic deletion of COX-2 or COX-2 inhibitor treatment leads to decreased small intestinal and
colorectal tumorigenesis (112,113) . Moreover, the terminal synthase of PGE2, mPGES-1, has
been shown to be functionally linked with COX-2 overexpression and PGE2 level elevation
during colon cancer development (114) . Studies in our lab have shown that genetic deletion of
mPGES-1 selectively blocks inducible PGE2 synthesis within the colonic mucosa, and
significantly suppresses genetic or carcinogen-induced intestinal cancer in mouse models
(115,116) , indicating mPGES-1 as a potential target for selective PGE2 suppression for CRC
prevention.

In addition, PGE2 may also play an important role within the tumor microenvironment by
facilitating

tumor-associated

angiogenesis

and

metastasis

during

CRC

progression.

Angiogenesis, the process that new blood vessels generate from existing system, is required for
providing blood perfusion and supplying oxygen/nutrient to local proliferating cells, therefore is
critical for both normal organogenesis (i.e. embryogenesis and adult tissue regeneration) and
cancer progression (117) . Angiogenesis is a dynamic process regulated by pro-angiogenic
factors, such as hypoxia-inducible factor-1α (HIF-1α), VEGF or CXCL1, and anti-angiogenic
factors, such as anti-angiogenic peptides (i.e. prolactin) and interferon-α (IFN-α). During tumor
progression, pro-angiogenic mechanism, mainly driven by HIF-1α upregulation and VEGF
overexpression, overrides anti-angiogenic effects, known as angiogenic switch, to promote
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neovascularization in tumor tissue and facilitate tumor growth. Pro-angiogenic factor
overexpression can be induced by hypoxia, pro-inflammatory cytokines or growth factors (118) .
Recent studies have shown that PGE2 signaling induces pro-angiogenic factor expression and
promotes angiogenesis in several malignancies, including breast, lung, ovarian, colon and
prostate cancers (119-122) . In breast cancer mouse model, mammary epithelial cancer cell
secreted PGE2 activates PKA pathway and induces VEGF expression in tumor stroma,
increasing micro-vessel density and promotes tumor progression (120) . Importantly, many
studies have shown that in CRC animal models, lack of PGE2 signaling by COX-2 knockout or
EP receptor antagonist treatment leads to significant decreased tumor vessel density and slower
tumor progression (123,124) . NSAIDs or selective COX-2 inhibitors treatment also block PGE2induced angiogenic factor production and suppress tumor-associated angiogenesis, suggesting
that PGE2 may play an important role in CRC angiogenesis (125) . Another aspect of PGE2 protumorigenic effects is associated with immunosuppression during tumor metastasis. Studies
showed that PGE2 could suppress cytotoxic (CD8+) T cell anti-tumor effect by directly downregulating dendritic cell-mediated antigen presentation both in vivo and in vitro (126,127) . PGE2
also reduces the level of anti-tumor cytokines (i.e. TNF-α, IFN-γ and IL-2) secreted by CD4+ T
cells (128) . Moreover, PGE2 has been shown to promote tumor immunosuppression by inducing
differentiation of Gr1+ CD11b+ myeloid-derived suppressor cells (MDSCs) and M2-like
macrophages in multiple malignancies including lung, breast and cervical carcinoma, to suppress
anti-tumor immunity and promote tumor metastasis (129,130) .

On the other hand, PGE2 has been shown important for the pro-tumorigenic functions of
the aforementioned CAFs. Gene expression analysis of colonic fibroblasts demonstrated a
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significant increase in the levels of COX-2 in CAFs compared to normal fibroblasts during
colorectal cancer initiation and growth (66,131-133) . The work by Konstantinopoulos and
colleagues (134) suggested that the up-regulation of COX-2 in colorectal cancer-associated
fibroblasts is associated with activation of AP-1 and NF-kB transcription factors; Studies by the
Lance group (131,135-138) and Zhu group (73) showed that COX-2 expression in CAFs can be
induced by pro-inflammatory factors including IL-1β, TNF-α, deoxycholic acid and HGF
through PKC-mediated mechanisms. Increased COX-2 expression and PGE2 secretion by CAF
promotes the proliferation and invasiveness of epithelial colon cancer cells in a paracrine
manner, partially by activation of EP4 receptor signaling in cancer cells (139) . Pre-treatment of
cancer cells with COX-2 inhibitors may abolish the pro-tumorigenic function of CAFs and
suppress colon cancer cell proliferation and invasion (73,139) . Overexpression of COX-2 has
also been observed in invasive adenocarcinomas and liver metastases in advanced colon cancer
patients (132,140) , suggesting that COX-2 may also be an important modulator the in
metastasis-promoting effects of CAFs (64) .

Overall, these studies suggest that PGE2 plays an important role in CRC tumorigenesis
and may be a potent target for CRC prevention. However, clinical studies demonstrate that longterm intake of NSAIDs could inhibit either COX-1 activity and suppresses platelets TXA2
production, or block COX-2 mediated PGI2 generation, thereby adversely affecting
cardiovascular homeostasis and resulting in severe side-effects, such as increased risk of stroke,
heart attack or GI bleeding (141,142) . Therefore, recently several selective mPGES-1 inhibitors
(i.e. MF63, PF-9184) have been developed and their efficacy as selective PGE2 suppressor for
CRC prevention while circumventing the side effects is under investigation.
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1.4

TREATMENT OF COLORECTAL CANCER

1.4.1

Clinical therapeutics
Despite the advances in preventive strategies, once an individual is diagnosed with CRC,

effective clinical treatments are critical for disease outcome and patient survival. As mentioned
in section 1.2.1, the clinical treatments for CRC vary based on the stage of diagnosis, but in most
cases, the therapeutic strategies are comprised of surgery and adjuvant radiotherapy or
chemotherapy. Recently, with a better understanding of the molecular mechanisms involved in
development of CRC, several targeted therapies have also been used as a complementary
treatment in clinical trials or first-line treatments for metastatic CRC patients (78) .

Surgery is the standard treatment for CRC diagnosed at all stages. For carcinoma in situ
and certain cases of stage I cancers (tumors that have not exceeded the upper third of the
submucosa within the colon wall), cancerous lesions can be removed by the endoscopic
microsurgery (143) . For more advanced primary tumors in colon or rectum, colectomy or total
mesorectal excision (TME), meaning the total removal of the affected section of colon or rectum,
usually accompanied by resection of nearby lymph nodes, are performed to reduce the risk of
tumor recurrence (144) . For patients diagnosed with metastatic CRC, the mostly common
metastatic site is the liver (approximately 20% of CRC cases have liver metastases). Liver
metastases resections are performed based on the evaluation of a number of prognostic factors,
including the numbers of metastases, extra-hepatic disease and sufficient liver reserves. With
effective treatments, there can be a 5-year disease free survival (DFS) in some patients (145) .
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Surgical treatment for stage II or more advanced CRC cases are usually accompanied by
adjuvant radiotherapy or chemotherapies. Due to the anatomic complexity in pelvis and absence
of serosa in rectum, preoperative or postoperative radiotherapy (radiotherapy fraction of 50.4Gy
in 28 fractions) are required to reduce the regional recurrence (146) . Concomitantly,
chemotherapies such as 5-fluorouracil (5-FU) and oxaliplatin, are used for both advanced rectal
and colon cancer, to prevent both local recurrence (rectal cancer) and distant metastasis (colon
cancer). Oxaliplatin is a platinum derivative and forms crosslinks with DNA strand, while 5-FU
is a thymidylate synthase (TS) inhibitor and blocks DNA synthesis. These conventional
chemotherapeutic agents attack rapidly-proliferating cells by inhibiting DNA/RNA synthesis or
microtubule function, resulting to cell death and tumor growth suppression. Due to the adverse
effects on normal proliferating cells, in clinical settings, these chemotherapeutic agents are
usually given in combination, such as FOLFOX (5-FU, oxaliplatin, folinic acid), or CapeOx
(capecitabine with oxaliplatin) (147) . Administration of chemotherapy of 6 months is known to
improve patient survival by approximately 10% to 15% (148) . However, due to their high
toxicity, the use of certain agents (i.e. oxaliplatin) in patients with lower tolerance (aged 70 or
older) is highly limited (16) . Another clinical problem is treatment failure, as tumor develops
resistance to chemotherapy (chemo-resistance), which leads to lack of response or tumor
recurrence. Chemo-resistance is more common among advanced CRC patients; most of the
metastatic colorectal patients develop resistance against chemotherapy within 8 months (149) .
The chemo-resistance of CRC and possible mechanisms will be discussed in the following
sections in detail.
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Besides surgery and conventional adjuvant therapies, recent advances in molecular
mechanisms of colorectal carcinogenesis and progression has inspired the development of
targeted therapies, the therapeutic strategies aiming at specific targets critical for CRC
development. For example, monoclonal antibodies against EGFR (i.e. Cetuximab, Panitumumab)
or VEGF (Bevacizumab) have been developed to suppress EGF signaling and angiogenesis in
CRC and other malignancies (i.e. melanoma) (16) . Some clinical trials showed that the
combination of targeted therapies with conventional chemotherapy increases patient survival
with less toxicity, but their efficacy in CRC is controversial (103,150) . In addition, resistance to
targeted therapy also develops in advanced CRC patients, and more studies are required to
optimize these targeted therapies for clinical use (151) .

1.4.2

Chemo-resistance of colorectal cancer
Despite the impressive advances in cancer research and development of clinical

therapeutics in the past several decades, treatment failure due to resistance against chemotherapy,
known as chemo-resistance, remains one of the biggest challenges in the fight against cancer
(152) . In clinical settings, despite the standard application and modest initial response to
chemotherapy in advanced CRC patients, most metastatic CRC patients develop resistance
against current chemotherapeutic agents (i.e. oxaliplatin, 5-FU) and die from tumor metastasis
within 2 years (149,153) . Understanding the underlying mechanisms and developing novel
therapeutic strategies to overcome chemo-resistance, is a key question in the field of cancer
therapy (154) .
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There are two forms of cancer cell resistance to chemotherapy: primary or intrinsic
resistance which leads to non-response to initial drug treatment, and secondary or acquired
resistance which develops after initial response to drug treatment. Both types of resistance are
believed to result from genetic or epigenetic alterations in cancer cells. However, intrinsic
resistance is likely to be caused by genetic alterations existing prior to drug treatment, while in
the case of acquired resistance, changes in gene expression or epigenetic deregulation might be
induced by the initial drug treatment.

Multiple mechanisms have been shown to be involved in chemo-resistance, and the most
common forms are due to de-regulations of critical cell proliferation or survival signaling
pathways. Genetic mutations or altered DNA methylation result in either activation of oncogenes
or inactivation (“loss-of-function”) of tumor suppressor genes. Therefore, not only does these
genetic changes promote cell transformation and proliferation, but also provide cell survival
signals to render resistance against chemotherapy-induced cell death. For example, activating
mutations in PI3KCA leads to constitutive activation of the PI3K/Akt/mTOR pathway,
promoting cell survival upon stress (i.e. chemotherapy, radiation) (41) . On the other hand, in
some cancer cells, an important tumor suppressor PTEN, which regulates Akt pathway, is
inactivated via promoter methylation, leading to both intrinsic and acquired chemoresistance
(155) . Similarly, alterations in DNA repair pathways or their downstream apoptotic pathways,
such as gene mutations for either MMR proteins or B-cell lymphoma 2 (Bcl-2) protein family,
could also affect the cellular response to drugs and promote drug resistance in cancer cells (156)
.
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It is worth mentioning that when cancer cells exhibit reduced sensitivity to chemotherapy
after initial response, they are likely to develop resistance simultaneously to multiple
structurally/functionally unrelated drugs. This phenomenon is known as multidrug resistance
(MDR), which is mainly mediated by multidrug resistance proteins from the ATP-binding
cassette (ABC) transporter family, such as P-glycoprotein (MDR-1/P-gp or ABCB1) and
multidrug resistance protein 1 (MRP1 or ABCC1) (157) . ABC transporters work as membraneembedded efflux pumps for various drugs, and their expression can be induced by chronic
exposure of cancer cells to drugs (158) . Overexpression of these proteins will increase drug
efflux and lower the intracellular concentration of anti-neoplastic drugs, therefore reduce their
efficacy. MDR is one of the major mechanisms involved in CRC chemoresistance (159) .

Besides the commonly known mechanisms, recent studies have indicated that cancer
stem cells (CSCs) are not only important for tumor initiation, but also play key roles in tumor
recurrence after chemotherapy (160) . CSCs are defined as tumorigenic cancer cells with stem
cell like properties including slow proliferation, self-renew and differentiation abilities. CSCs are
found in a wide variety of malignancies including GI cancers and exhibit capability to drive
primary tumor initiation in xenograft mouse models (161) . As current chemotherapies mainly
target rapidly proliferating cells, CSCs are more resistant to cytotoxic drugs and able to mediate
tumor recurrence (expansion) after chemotherapy (162) . Other mechanisms such as MDR and
anti-apoptosis signaling have also been associated with CSC chemoresistance in colon cancer
(163) . Developing a better understanding of CSC-mediated chemoresistance mechanisms is
critical for enhancing chemotherapeutic efficacy and improving advanced CRC patient survival.
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The involvement of CSCs in colon cancer resistance against oxaliplatin will be discussed in
greater detail later in this dissertation.

1.4.3

Targeting PGE2 for treatment of colorectal cancer
As discussed previously (section 1.3.3), the multi-functional bioactive lipid PGE2 has

been well known for its various pro-tumorigenic effects in colorectal cancer initiation and
progression, and has provoked many studies as a potent target for CRC prevention (104) .
However, recent studies haves shown that PGE2 signaling may be involved in tumor response or
resistance to current anti-cancer therapies, suggesting that PGE2 or its selective synthase may
serve as potential targets for adjuvant therapy in cancer treatment (164) . For example, several
preclinical studies have shown that PGE2 suppression by NSAIDs or COX2 inhibitors, including
celecoxib and sulindac, could effectively enhance chemotherapy efficacy or even abrogate
chemo-resistance in various cancer types (165,166) . In recent neo-adjuvant clinical trials, the
combination of COX-2 inhibitors with standard breast cancer therapy aromatase inhibitors (AI)
have shown promising efficacy and safety for treatment of metastatic breast cancer (167) .

In colorectal cancer, the beneficial effect of PGE2 suppression has been confirmed in
multiple studies in which COX-2 inhibitors are combined with current chemotherapeutic agents,
including 5-FU and oxaliplatin. For example, Zhang and colleagues discovered that combination
of celecoxib and 5-FU significantly inhibited colon tumor growth via activation of cytochrome C
mediated apoptotic pathway in subcutaneous xenograft mouse model (168) . Lin and colleagues
demonstrated that combination of celecoxib and oxaliplatin could significantly reduce expression
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of survivin protein expression and increase cell death compared to oxaliplatin alone (169) .
Furthermore, studies by the Zhao group showed that addition of celecoxib not only increases cell
apoptosis and facilitates tumor shrinking, but also significantly reduces angiogenesis (VEGF
mRNA expression and microvessel density) in a mouse xenograft model of colon cancer (170) .
These combination therapy studies suggest that COX-2 inhibition could improve
chemotherapeutic efficacy in CRC. However, the side effects, including increased cardiovascular
risk, have become great hurdle for clinical application of COX-2 inhibitors (142) .

Fortunately, the beneficial effect of COX-2 inhibition in combined treatment of CRC is
possibly due to blockade of PGE2 signaling. Studies have shown that PGE2 promotes colon
cancer cell growth and inhibits cell apoptosis through PI3K pathway activation (171,172) .
Interestingly, besides chemotherapy-induced cell death, Tessner and colleagues found that PGE2
could also reduce radiation-induced epithelial apoptosis in mouse small intestine and human
colon cancer cell line, possibly through AKT mediated anti-apoptotic pathway (173) . These
studies suggest that PGE2 signaling could promote cancer cell survival in different conditions
(spontaneous or under stress), implying that the aforementioned COX-2 inhibition may enhance
oxalipatin efficacy possibly by suppressing PGE2 mediated anti-apoptotic mechanisms.

Besides cell survival signaling, the COX-2/PGE2 pathway has also been associated with
CSC-mediated cancer chemoresistance (164,165) . Several studies showed that a combination
treatment of NSAIDs or COX-2 specific inhibitors could enhance the efficacy of chemotherapies
on colon cancer cells, while long-term use of aspirin or celecoxib has been shown to improve the
overall survival of advanced CRC patients in several clinical trials (174-176) , indicating the
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potential clinical benefits of COX-2 inhibition in colon cancer therapy. These findings suggest
that PGE2 may play an important role in colorectal tumor response to chemotherapy, and
targeting PGE2 could provide a novel strategy to enhance treatment efficacy and combat chemoresistance. In my thesis study, the significance of PGE2 signaling in colorectal cancer cell
survival will be examined in depth, and the potential of targeting PGE2 as adjuvant therapeutic
strategy to enhance the efficacy of oxaliplatin or circumventing oxaliplatin resistance in CRC
will be evaluated.

1.5 Genetically engineered mouse models of colorectal cancer

1.5.1

Germline genetically mutant models
Although cell culture system is widely used for mechanism studies and early phase/high-

throughput drug screening, preclinical animal models are critical in vivo platforms for biomarker
identification and drug development in colorectal cancer research, given their great advantages in
both time and cost. There are mainly two types of mouse CRC models, xenograft models and
genetically engineered mouse models (GEMMs). Xenograft models are built by subcutaneously
or orthotopically transplanting in vitro passaged CRC cells or patient-derived colorectal tumors
into immunodeficient mice. Although these models are simple to use and relatively cheaper than
GEMMs, their drawbacks such as host immune deficiency and tumor-stromal mismatch have
limited their value in testing and predicating the efficacy of novel anti-cancer drugs. On the
contrary, GEMMs recapitulate spontaneous colorectal tumorigenesis in immunocompetent mice
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by genetically modifying critical genes in human CRC development (i.e. APC, KRAS), thus
circumvent the limitations of xenograft models.

The very first GEMM for CRC was developed in 1990s. Moser and colleagues
discovered a mouse lineage that exhibits inherited predisposition to spontaneous intestinal
tumorigenesis, and named it Min (multiple intestinal neoplasia) (177) . Min mice were then
confirmed to carry a nonsense mutation in APC genes, which is analogous to the APC mutations
found in FAP patients and some sporadic CRC patients (178) . Ever since, more CRC mice
models have been established with various APC germline mutations (179) . Because
homozygous APC mutations are proved embryonically lethal, all these mice models are
heterogeneous (180) . Interestingly, despite the variations in sizes and numbers, most polyps or
adenomas developed in these APC mutated mice are located in small intestine rather in colon.

Although APC gene mutations are critical for initiating human colorectal tumorigenesis,
subsequent genetic/epigenetic alterations in other key genes (i.e. KRAS, TP53, PTEN) are
required for carcinoma development. Recently, different GEMMs have been established by
crossing APC mutant mice with other mutant mice, providing great models for studying the role
of different factors in multistep colorectal carcinogenesis. For example, while APCMin+/- mice
mostly develop benign intestinal adenomas, invasive carcinomas are developed in APCMin+/PTEN+/- mice, suggesting that PTEN loss-of-function is critical for malignant transformation in
colorectal carcinogenesis (181) . On the other hand, genetic deletion of COX-2 or mPGES-1
reduces intestinal polyp formation in Min mice, indicating the significance of PGE2 synthesis in
intestinal tumorigenesis (113,116) . In addition to mechanism studies, germline APC mutant
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mice have also been used widely in development of preventive and therapeutic strategies for
human CRC (182) . However, due to the inherent heterogeneity in tumor growth, it is difficult to
determine if the tested drug is preventing tumor formation or regress established tumors in these
germline mutant mice, therefore creating hurdles for implementation of preclinical results into
clinical applications.
1.5.2

Cre recombinase-based genetic models
To circumvent the embryonic lethality and other limitations of germline mutant mice

models, another type of GEMMs, the inducible genetic mice models, were created using CreloxP system. This system is established by employing a loxP-flanked transcriptional/translational
stop cassette (neostop) located within the first intron of a target gene (with desirable mutations).
In the absence of Cre, expression of the mutant gene is suppressed by neostop. When Cre
recombinase gets activated and removes the neostop, the mutated gene will be expressed,
providing conditional gene modifications (183) . The first conditional APC knockout mice were
generated by Shibata and colleagues through injection of recombinant adenovirus expression Cre
recombinase into mice colons (184) . Cre-mediated conditional knockout of APC resulted in
colonic adenoma formation in 4 weeks and invasive adenocarcinoma development after 1 year.
The adenovirus expressing Cre method was further modified by Hung and colleagues to achieve
more reproducible distal colonic adenoma formation to test drugs for sporadic CRC treatment
(185) .

In addition, promoter-driven Cre recombinase expression has also been used to generate
tissue-specific gene modification in mice. In 2004, Robine group established an intestinal
epithelium-specific Cre expressing model by inserting Cre under the control of Villin promoter
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(186) . This Villin-Cre system has been widely used for studying the functions of different genes
in colorectal carcinogenesis, including APC, KRAS, TGFβ (187,188) . Besides Villin promoter,
other promote has also been used combined with Cre to achieve more specific genetic
modifications in CRC GEMMs (189,190) . Moreover, the applications of tamoxifen-regulated
Cre expression allowed the generation of inducible GEMMs and further strengthened their
specificity as preclinical platforms for mechanism studies and drug development.

1.6

EXPERIMENTAL DESIGN

Specific Aim 1. To assess the significance of PGE2 signaling in oxaliplatin resistance in
human CRC cells.
The efficacy of oxaliplatin, the first-line platinum-derivative for CRC treatment, has been
strongly limited by acquired resistance developed in advanced CRC patients after long-term
exposure, while the direct mechanism for oxaliplatin resistance remains unclear. Recent studies
showed that the co-treatment of COX-2 inhibitors could improve the efficacy of oxaliplatin on
suppressing CRC cell proliferation and colorectal tumor growth, in vitro and in vivo,
respectively. In this aim, we want to determine the significance of PGE2, the main product of
COX-2 pathway, in CRC oxaliplatin resistance using oxaliplatin resistant (OXR) human colon
cancer cells. The metabolism of PGE2 in resistant cells and the effect of PGE2 suppression on
oxaliplatin cytotoxicity will be determined. The significance of each EP receptor signaling in
oxaliplatin resistance will also be tested. This work will reveal the direct involvement of PGE2 in
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oxaliplatin resistance and evaluate the potential of PGE2 signaling as target for CRC adjuvant
therapy.

Specific Aim 2. To investigate the association between PGE2 signaling and potential chemoresistance mechanisms in human CRC in vitro.
Given the clinical obstacles associated with oxaliplatin resistance in advanced CRC
patient treatment, developing a better understanding of its underlying molecular mechanisms of
resistance is critical for novel target discovery and the further development of adjuvant
therapeutic strategies. Besides the conventional mechanisms (i.e. MDR, apoptotic regulation),
recent studies have suggested that cancer stem cells (CSCs) may be involved in oxaliplatin
resistance. In this aim, we will assess the stem-like properties of oxaliplatin resistant (OXR)
colon cancer cells, and determine the significance of PGE2 and its receptor signaling in CSC
subpopulation of the heterogeneous OXR cancer cells. Another mechanism associated with
chemoresistance is through modulation of oxidative stress. In this aim, we also will investigate
the modulation of reactive oxygen species (ROS) in OXR cells and evaluate the effect of PGE2
signaling suppression on oxaliplatin-induced oxidative stress and cytotoxicity in OXR colon
cancer cells.

Specific Aim 3. To determine the histological and molecular alterations of pre-neoplastic
lesions in the inducible BRAFV600E mutation mouse model.
The colonic pre-neoplastic lesions, such as aberrant crypt foci (ACF), are regarded as
precursors to CRC. Constitutive BRAF activation has been shown to be associated with the
“alternative” serrated pathway of CRC, and oncogenic BRAF mutations are found in hyperplastic
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ACFs, supporting the hypothesis of a “hyperplastic ACF-hyperplastic polyp-serrated
adenoma/carcinoma” pathway. To evaluate the significance of BRAF mutation for early
neoplasia of serrated CRC, in this aim, we generated a tamoxifen-induced BRAFV600E mutation
specifically in intestinal Lgr5+ cells in B6 mice, and characterized the histological and molecular
alterations of pre-neoplastic lesions. This study will demonstrate the significance of the BRAF
mutation in colorectal serrated neoplasia and help establish the BRAF mutation-driven ACF
model for development of CRC preventive strategies.
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CHAPTER 2

TARGETING PGE2 SIGNALING IN OXALIPLATIN RESISTANT HUMAN COLON
CANCER CELLS

2.1 INTRODUCTION

Prostaglandin E2 (PGE2), one of the most abundant products of prostaglandins pathways
in human body, has been shown tightly involved in human colorectal caricinogenesis (125) .
PGE2 level is elevated in CRC patients, resulting from the hyperactivation of its synthesis
pathway. Two of the key enzymes for PGE2 generation, cyclooxygenase-2 (COX2) and
microsomal prostaglandin E synthase-1 (mPGES1) have been shown overexpressed in both
colorectal cancer cells and preclinical CRC models (191) . Since PGE2 exerts multiple protumorigenic functions, including promoting cancer cell proliferation and survival, assisting
tumor angiogenesis and metastasis, suppressing anti-tumor immunity, it has been regarded as a
potent target for CRC prevention (106) . Large scale randomized clinical trials have
demonstrated that long-term intake of nonsteriodal anti-inflammatory drugs (NSAIDs) or COX-2
inhibitors could reduce CRC incidence by 30% among high-risk population (105) .

Recently, studies suggested that PGE2 might also play important role in tumor response
to chemotherapy. Preclinical studies have suggested that PGE2 suppression by COX2 inhibitors
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such as celecoxib and sulindac could effectively enhance chemotherapy efficacy, even abrogate
chemo-resistance in preclinical models for breast cancer and bladder cancer (165,167) . In
addition, treatment of COX-2 inhibitors showed synergistic effect on tumor growth inhibition
when combined with chemotherapeutic drugs (i.e. oxaliplatin or 5-FU) in human cancer cell
studies or CRC mice models, suggesting that the COX-2/PGE2 pathway may be a potential target
to enhance chemotherapy efficacy and combat chemo-resistance (168-170) . However, the
adverse effects of COX-2 inhibitors, such as increased cardiovascular risk and GI bleeding, has
resulted to strong limitation for its clinical use (141) . Therefore, further studies are needed to
discover more specific targets for circumventing the adverse effects but retaining the anticancer
benefits of PGE2 suppression.

To solve this problem, many studies have focused on identifying the specific receptors of
PGE2 and signaling pathways that mediate the biological functions of PGE2. There are four
pharmacologically distinct, plasma membrane G-protein coupled receptors (GPCR) that binds to
PGE2 on cell membrane, known as EP receptors (EP1, EP2, EP3, and EP4). Each EP receptor
activates different downstream signaling pathways, resulting to different functions in both
normal and malignant cells (192,193)

(Figure 4). Recent studies suggested that each EP

receptor plays different role during colorectal tumor development. For example, by crossing
selective homozygous EP gene knockout mice with APC mutant mice, Taketo and colleagues
found out that EP2 accelerates intestinal polyposis in APC mutant mice, while EP1 and EP3
receptor signaling don’t affect intestinal polyp formation (194) . In contrast, Wakabayashi group
revealed that down-regulation of EP3 receptor expression resulted to higher incidence of
carcinogen-induced mouse colon tumor generation (195) . Moreover, studies have shown that
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EP4 receptor, although originally identified as similar to EP2 receptor, could couple with Giα,
activate phosphatidylinositol 3-kinase (PI3K) and β–catenin, thus plays unique roles in many
physiologic and pathophysiologic events (196) . Specifically, EP4 receptor signaling has been
extensively studied for its pro-tumorigenic functions, including promoting cell proliferation and
survival, tumor metastasis, and suppressing antitumor immunity (197,198) . These findings
suggest that EP receptors play important roles in CRC progression, but their functions may be
situation dependent, so it is important to identify the significance of each EP receptor and their
downstream signal pathways in different CRC models.

Given the results of studies on COX-2 inhibitors and PGE2 in CRC chemotherapeutics,
we hypothesize that PGE2 promotes human colorectal cancer cell survival against oxaliplatin
treatment via its downstream receptors (EP1-4) signaling; blocking PGE2-EP signaling pathways
could enhance oxaliplatin efficacy on resistant human CRC cells. To test our hypothesis, in the
following study, we evaluated the significance of PGE2 in oxaliplatin resistance using an
established oxaliplatin resistant cell culture model. Oxaliplatin resistant (OXR) human CRC cells
were generated from chemo-naïve human CRC cell line HT29, by chronic exposure of increasing
concentrations of oxaliplatin. We compared both PGE2 metabolism pathways in both resistant
and parental cell lines to build the associated between PGE2 metabolism and oxaliplatin
resistance. The causation was confirmed by measuring oxaliplatin efficacy on OXR cells after
PGE2 suppression via blocking its terminal synthase mPGES-1 expression. We also examined
the roles of each EP receptor in oxaliplatin resistance using highly selective EP receptor
antagonists and evaluate EP4 receptor downstream signaling in both OXR and chemo-naïve cell
lines. By identifying the specific EP receptor signaling involved in oxaliplatin resistance, further
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studies may discover potential targets for adjuvant therapy to maximize the benefit for
overcoming oxaliplatin resistance while avoiding side effects of PGE2 suppression in CRC
treatment.
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Adapted from Rundhaug, Simpler, Surh and Fischer, Cancer Metastasis Rev, 2011

Figure 4. Signaling pathways activated by the EP receptors. EP receptors are G-protein
couple receptors (GPCRs) located on the cell membrane. When binding to the ligand PGE2, EP1
activates phospholipase C (PLC), which catalyze the generation of 1,2-diacylglycerol (DAG) and
inositol 1,4,5-trisphosphate (IP3), which releases Ca2+. DAG activates the protein kinase C
(PKC) pathway and promotes cell proliferation. EP2 and EP4 both activate adenylate cyclase
(AC), which increase cAMP generation and PKA pathway activation. However, EP3 inactivates
AC and suppress PKA signaling. EP4 also activates PI3K/AKT pathway, which increases cell
proliferation and survival.

48

2.2 MATERIALS AND METHODS

Materials. Human colon cancer cell lines HT29 and RKO were obtained from the American
Type Culture Collection (ATCC, Manassas, VA). The HT29 Oxaliplatin-resistant (OXR) cell
line was generated as previously described (199) . Briefly, chemo-naïve HT29 cells were
exposed to increasing concentrations of oxaliplatin over a three-month time-frame, with the final
concentration maintained at 2µM. Cell culture media and serum were purchased from Life
Technologies (Carlsbad, CA). Oxaliplatin, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis,
MO). PGE2, EP receptor selective antagonists and EP4 receptor agonist were purchased from
Cayman Chemicals (Ann Arbor, MI).

Cell Culture Conditions. Human cancer cell lines were cultured at 37°C in a humidified
atmosphere of 5% CO2 in MEM, supplemented with 10% fetal bovine serum (FBS), 1%
penicillin-streptomycin, L-Glutamine, MEM vitamin solution, sodium pyruvate and MEM nonessential amino acids. Oxaliplatin resistant cells were maintained in 2µM oxaliplatin, but were
cultured in oxaliplatin-free media at least 24 hours prior to experimentation. Cells were
confirmed to be free of Mycoplasma using Mycoplasma Detection Test (200) . All experiments
were performed at 70% cell confluence with no more than 20 cell passages. Results from all
studies were confirmed in at least three independent experiments.

Cell Viability Assay. Cell sensitivity to drugs was assessed using cholorimetric 3-(4,5Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described previously.
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Briefly, cells were seeded in 48-well plates overnight and treated with or without drugs. After 72
hours, 100µl MTT solution (Sigma) was added to each well and incubated for 1h at 37°C.
Medium was then aspired and 300µl DMSO was added. Colorimetric analysis was performed at
a wavelength of 570nm using a standard microplate reader. IC50 curves were generated with
GraphPad Prism (software version 5.0c) using variable slope model.

Gene Knockdown Using Small Interfering RNA (siRNA). Cells were seeded in 6-well plates
or 48-well plates overnight. Cell layers were rinsed twice with sterile PBS followed by the
addition of OPTI-MEM (Life Technologies) containing K2 transfection reagent (1µl/100µl,
Biontex) and siRNA against mPGES-1 (5nM siGENOME SMARTpool siRNA targeting human
PTGES, Target Sequence: GCA CGC UGC UGG UCA UCA A, GGG CUU CGU CUA CUC
CUU U, GGA UGC ACU UCC UGG UCU U, UGG CAC ACA CCG UGG CCU A) or control
siRNA (5nM siGENOME Non-Targeting siRNA) (Dharmacon). After overnight incubation, the
media was changed to MEM supplemented with 10% FBS. After 48-72h, culture medium was
removed and stored at -80°C for subsequent PGE2 level determination, and the cells were
harvest for RNA isolation or protein extraction.

RNA Isolation and Reverse Transcription Polymerase Chain Reaction (RT-PCR). Total
RNA was isolated using the RNeasy Mini kit (Qiagen Inc.). cDNA was synthesized using
Superscript III according to the manufacturer’s protocol (Invitrogen) mRNA expression levels of
genes of interest were examined with iTaq Universal SYBR Green Supermix (Bio-Rad
Laboratories, Inc.) on the ABI-7500 platform (Applied Biosystems). The levels of RNA
expression were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The
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primers used for PCR amplification were: 5’-GAA GAA GGC CTT TGC CAA C-3’ and 5’GGG TTA GGA CCC AGA AAG GA-3’ for mPGES-1; 5’-TCA TGC TCA ACG AGA AGG
AG-3’ and 5’-CTC GCG GAC AAT GTA GTC AA-3’ for mPGES-2; 5’-AAG TCG ACT CCC
TAG CAG CA-3’ and 5’-TCC CTT CGA TCG TAC CAC TT-3’ for cPGES; 5’-CAC AAC
ACT TCA CCC ACC AG-3’ and 3’-CGG GTA CAT TTC TCC ATC CA-5’ for COX-1; 5’TGA AAC CCA CTC CAA ACA CA -3’ and 5’-GAG AAG GCT TCC CAG CTT TT-3’ for
COX-2; 5’-GTA AAG CTG CCC TGG ATG AG-3’ and 5’-TGT CCA GTC TTC CAA AGT
GGT-3’ for 15-PGDH; 5’-ACA ACT TTG GTA TCG TGG AAG G -3’ and 5’-CAG TGA GCT
TCC CGT TCA G-3’ for GAPDH. For each experiment, PCR amplifications with no cDNA
were performed as negative controls. The levels of RNA expression were normalized to
GAPDH. PCR products were analyzed on 2% agarose gel with ethidium bromide (E-gel,
Invitrogen), together with 1 kb plus DNA ladder (Invitrogen).

Protein Extraction and Western Blotting. To isolated protein, cultured cell monolayers were
washed twice with ice-cold PBS and treated with lysis buffer (1xRIPA buffer, 1:50 protease
inhibitor and 1:50 phosphatase inhibitor, Sigma) for 5 minutes on ice. The cell lysates were
ultrasonicated (Sonic Dismembrator Model 100, Fisher Scientific, MA) and centrifuged. The
protein concentration was determined using the Protein Assay solution (Bio-Rad Laboratories,
Inc., CA). 30µg of protein was loaded for electrophoresis (Bio-Rad) and transferred to PVDF
membrane (Immobilon-P membrane, EMD Millipore, MA). The membranes were blocked in 5%
non-fact dry milk in TBST (1x TBS, 0.1% Tween 20) for 1 hour. Blots were incubated with
primary antibodies overnight at 4°C and HRP-conjugated secondary antibodies for 1 hour at
room temperature. HRP was visualized with enhanced luminal reagent (Immobilon Western,
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EMD Millipore, MA). Antibodies used for Western blotting analyses were as follows: rabbit
anti-mPGES-1 (Abnova, Taiwan), rabbit anti-COX-2, rabbit anti-EP1, rabbit anti-EP2, rabbit
anti-EP3, rabbit anti-EP4 (Cayman Chemicals, MI), rabbit anti-cleaved PARP, rabbit antiphospho-Akt, rabbit anti-Bcl2, rabbit anti-Bax (Cell Signaling Technologies, MA), mouse anti-β
actin (Sigma, MO).

PGE2 ELISA Essay. To measure total secreted PGE2 level, cell culture supernatants were
collected and PGE2 concentrations were measured by commercial ELISA kit (Cayman Chemical,
MI) according to manufacturer’s protocol.

Flow Cytometry and Cell Cycle Analysis. Drug-treated cells or control cells were collected and
fixed in cold methanol, and stained with propidium iodide (PI) or 7-AAD (Sigma, MO). After
staining, Cells were collected and analyzed for DNA content using LSR-II Flow Cytometer (BD
Biosciences, CA). All Analyses were performed in triplicate and 50,000 gated events/sample
were counted using FlowJo 10.3 software (FlowJo LLC). Cell Cycle stages and apoptosis rate
were analyzed using ModFit LT 3.3.11 software (Verity Software House).

Statistical Analysis. Data from all experiments was analyzed using the Student’s t test or twoway analysis of variance (ANOVA) when appropriate for analysis by GraphPad Prism (software
version 5.0c). For MTT assay, 50% inhibitory concentrations of oxaliplatin were calculated and
compared using extra sum-of-squares F test. Results were considered as statistically significant
at a P value of less than 0.05. All statistical tests were two-sided.
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2.3 RESULTS

HT29 oxaliplatin-resistant (HT29 OXR) cells exhibited lower sensitivity to both
oxaliplatin and 5-FU. HT29 oxaliplatin-resistant (HT29 OXR) cells were generated by chronic
exposure (up to 3 months) of parental HT29 cells to increasing concentrations of oxaliplatin,
with a final concentration maintained at 2µM (199) . Long-term treatment with low
concentration of oxaliplatin induces a significant increase in colon cancer cell survival in the
presence of oxaliplatin (IC50 value: 134.1µM compared to 3.4µM; P<0.0001), compared to the
chemo-naïve parental cell line (Fig. 5A). The sensitivity of both HT29 OXR cells and HT29
parental cells to another first-line CRC chemotherapy, 5-FU were also tested. The resistant cells
also showed significantly less sensitivity to 5-FU cytotoxicity compared to the parental cells
(IC50 value: 67.35µM compared to 12.66µM; P<0.0001)(Fig. 5B). These results suggest that
certain molecular mechanism in OXR cells may be involved in both oxaliplatin resistance and 5FU resistance.
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Figure 5. HT29 oxaliplatin-resistant (HT29 OXR) cells exhibited higher cell survival rate
upon treatment of both oxaliplatin and 5-FU. (A) HT29 PAR and OXR cells were treated with
increasing concentrations of oxaliplatin for 72 hours. (B) HT29 PAR and OXR cells were treated
with increasing concentrations of 5-FU for 72 hours. Cell viability was assessed using the MTT
assay.
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Anti-apoptotic pathway activation is upregulated in oxaliplatin resistant cells
compared to parental cell line. To understand the direct mechanisms involved in
chemoresistance in OXR cells, we tested anti-apoptotic pathway activation status in both OXR
cells and parental cells without presence of oxaliplatin. Compared to parental cells, the OXR
cells showed significant up-regulation of AKT phosphorylation level, and concomitant higher
Bcl-2/Bax ratio at basal level (Fig. 6A), suggesting an activation of anti-apoptotic pathway in
OXR cells. We also tested the protein level of MDR-1 (P-glycoprotein), the most common
multidrug resistance protein from ABC transporter family. Surprisingly, there was no difference
in the protein levels of MDR-1 in both cell lines (Fig. 6B), suggesting that MDR mechanism may
not be playing an important role in chemoresistance of the OXR cells.
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A.

B.

Figure 6. Oxaliplatin resistant cells demonstrated activation of anti-apoptotic pathway but
not multi-drug resistance mechanism. Both HT29 OXR cells and HT29 PAR cells were
cultured in oxaliplatin free condition for 72 hours before protein extraction. (A) Western Blot
analysis for the phosphorylated AKT, Bcl-2 and Bax protein. (B) Western Blot analysis for
MDR-1 protein in both cell lines. β-actin was used for standard normalization.
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Deregulation of PGE2 metabolism in oxaliplatin resistant colon cancer cells. Many
studies have suggested that PGE2 signaling promotes cell anti-apoptotic pathway activation in
CRC. Recently, metabolic deregulation of PGE2 has been associated with chemotherapy efficacy
and chemoresistance in cancer. To determine the PGE2 metabolism during the development of
chemoresistance, we measured the secreted PGE2 levels in both parental (chemo-naïve) HT29
cells and the oxaliplatin-resistant derivative (HT29 OXR) cells. We found that HT29 OXR cells
maintained higher level of secreted PGE2 (~3 fold increase; P<0.05) compared to the parental
cell line (Fig. 7A), suggesting significant deregulation in PGE2 metabolism in HT29 OXR cells.

To understand the mechanism of PGE2 up-regulation in OXR cells, we measured mRNA
expression and protein levels of several key enzymes involved in PGE2 metabolism. Compared
to the parental cells, HT29 OXR cells exhibited increased expression of COX-2 (18-fold;
P<0.001) and the terminal PGE2 synthase, microsomal prostaglandin E synthase-1 (mPGES-1)
(7-fold increase; P<0.001), respectively, suggesting activation of the PGE2 synthesis pathway in
these cells. Meanwhile, a significant reduction of both mRNA (50% reduction; P<0.0001) and
protein levels of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), the key PGE2 catabolic
enzyme, were detected in HT29 OXR cells compared to the parental cell line, indicating downregulation of PGE2 catabolism (Fig. 7B-C). However, there is no difference in the mRNA
expression level of COX-1, mPGES-2 and cPGES (Fig. 7D). Taken together, our results
demonstrate a marked loss of metabolic control over PGE2 in oxaliplatin resistant colon cancer
cells, suggesting an associated between PGE2 deregulation and oxaliplatin resistantance.
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Figure 7. Deregulation of PGE2 metabolism in HT29 OXR cells. Both HT29 OXR cells and
HT29 PAR cells were cultured in oxaliplatin free condition for 72 hours before supernatant
collection and RNA/protein extraction. (A)Total secreted PGE2 levels in both cell lines
measured using ELISA. (B) mRNA expression and (C) cellular protein level of COX-2, mPGES1 and 15-PGDH in both cell lines were determined using RT-PCR and Western Blotting
analysis, respectively. (D) mRNA expression of COX-1, mPGES-2 and cPGES were measured
using RT-PCR analysis.
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PTGES knockdown sensitizes HT29 OXR cells to oxaliplatin. In order to determine
whether PGE2 suppression affects oxaliplatin resistance in human CRC, we further inhibited
PGE2 synthesis by OXR cells via siRNA-mediated knockdown of PTGES, the gene encoding
mPGES-1. Significant reductions in both mRNA expression (~70% reduction; P<0.01) and
protein levels of mPGES-1 were found 48 hours after siRNA treatment (Fig. 8A-B).
Concomitantly, gene silencing of mPGES-1 in HT29 OXR cells reduced PGE2 synthesis by
~85% (P<0.001) (Fig. 8C).

PGE2 suppression through PTGES knockdown increased cell sensitivity to oxaliplatin
treatment (IC50) by 33%, as measured by the MTT cell viability, compared to the non-targeting
(NT) siRNA treated HT29 OXR cells (Fig. 9A). In addition, PTGES knockdown also reduced
phosphorylation of AKT in HT29 OXR cells, suggesting that PGE2 suppression may affect the
activation of a key survival pathway in oxaliplatin resistance of human CRC (Fig. 9B).
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Figure 8. SiRNA silencing of mPGES-1 suppressed PGE2 synthesis in HT29-OXR cells.
HT29 OXR cells were treated with PTGES or Non-targeting (NT) siRNA (0.1µg siRNA per
2.5x104 cells) for 48 hours following by RNA/protein extraction and supernatant collection. (A)
mRNA expression and (B) protein level of mPGES-1 were measured by RT-PCR analysis and
Western Blotting analysis, respectively. (C) Total secreted PGE2 level was measured by ELISA.
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Figure 9. PGE2 suppression sensitizes HT29 OXR cells to oxaliplatin cytotoxicity. (A)HT29
OXR cells were treated with increasing concentrations of oxaliplatin for 72h after PTGES
siRNA or non-targeting(NT) siRNA treatment. Cell viability was assessed using the MTT assay.
Cytotoxicity rate was defined as the percentage of dead cells in oxaliplatin treated cells
compared to untreated cells. (B) Western Blot analysis for the indicated protein extracted from
HT29 OXR cells treated with PTGES siRNA or non-targeting (NT) siRNA.
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A selective EP4 receptor antagonist sensitizes resistant cells to oxaliplatin. The
biological function of PGE2 is controlled in part by its direct binding to a set of G-proteincoupled receptors (GPCRs): EP1, EP2, EP3 and EP4 receptors (192) ; these EP receptor subtypes
signal through distinct downstream pathways to afford different cellular functions. To understand
the mechanism of PGE2 suppression in oxaliplatin resistance, we ought to determine the
significance of each EP receptor in OXR cells. First we measured the protein levels of the EP
receptors between chemo-naïve HT29 parental cells and OXR cells, but did not see significant
difference (Fig. 10A). To determine the effects of specific EP receptor inhibition in OXR cells,
we blocked EP receptor activity using a set of selective EP receptor antagonists and assessed the
cytotoxicity of oxaliplatin via cell viability assay. The addition of the EP4 antagonist L-161,982
(10µM) significantly increased oxaliplatin induced cytotoxicity (~1.7-fold increase; P<0.05)
compared with oxaliplatin alone in HT29 OXR cells. In contrast, addition of L-161,982 had no
significant effect on oxaliplatin efficacy on HT29 parental cells (Fig. 10B; Table 1). Selective
blockade of the other EP receptors (1-3) failed to demonstrate a synergistic effect on oxaliplatin
cytotoxicity (Fig. 10C).

Oxaliplatin exerts its cytotoxicity by inducing extensive DNA damage (201) . This in turn
causes cell cycle arrest and intrinsic cell apoptosis (202) . To gain further insight into potential
mechanisms by which EP 4 receptor blockade may synergize with oxaliplatin-induce cell death,
we measured the effects of the EP4 antagonist L-161,982 on oxaliplatin-induced cell cycle arrest
and apoptosis using FACS analysis. The combination treatment of L-161,982 (10µM) and
oxaliplatin for 48 hours significantly increased the apoptotic cell population of OXR cells
compared to oxaliplatin alone (Fig. 11A; Table 2 ). To evaluate the level of cell apoptosis in
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treated HT29 OXR cells, we measured the protein markers involved in cell apoptosis and
survival pathway. The levels of PARP cleavage induced by oxaliplatin were increased by L161,982 treatment, indicating increased apoptosis of HT29 OXR cells. In contrast, the
phosphorylation of AKT and the Bcl2/Bax ratio were reduced, suggesting reduction of cellular
survival pathway activation in response to oxaliplatin (Fig. 11B). Taken together, our results
show that selective inhibition of EP4 receptor activity by L-161,982 suppresses cell survival and
synergistically enhances oxaliplatin cytotoxicity in oxaliplatin resistant cells.
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80
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Figure 10. Selective EP4 blockade synergistically enhanced oxaliplatin efficacy in HT29
OXR cells. (A) Both HT29 OXR cells and HT29 PAR cells were cultured in oxaliplatin free
condition for 72 hours before protein extraction. The protein levels of all EP receptors (1-4) were
measured using western blotting analysis. (B) HT29-OXR cells or HT29 PAR cells were either
treated with different concentrations of oxaliplatin alone (control) or co-treated with 10µM L161,982 for 72h. Cell viability was assessed using the MTT assay. Cytotoxicity rate was defined
as the percentage of dead cells In oxaliplatin treated cells compared to untreated cells. (C) HT29
OXR cells were either treated with increasing concentrations of oxaliplatin alone (control) or cotreated with 10µM SC-51089 (EP1 selective antagonist)/ 10µM PF-04418948 (EP2 selective
antagonist)/ 10µM L-798,106 (EP3 selective antagonist) for 72h. Cell viability was assessed
using the MTT assay.
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Table 1. 50% inhibitory concentrations of oxaliplatin in both cell lines were measured
using MTT assay.

Cells

Control

L-161,982 10µM

HT29 PAR

3.435

5.34

HT29 OXR

143.1

104.2***
(***P<0.0001;n=4)
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A.

B.

Figure 11. Selective EP4 blockade increased oxaliplatin induced cell apoptosis in HT29
OXR cells. HT29 OXR cells were treated with vehicle control or 25µM oxaliplatin alone or
25µM oxaliplatin+10µM L-161,982 for 48h followed by PI staining or protein extraction. (A)
Cell cycle analysis was done using flow cytometry. (B) Levels of cleaved PARP, phosphorylated
AKT and Bcl2/Bax protein were detected using western blotting analysis.
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Table 2. The percentages of cycle stages and apoptosis rate in each group were calculated
by computer modeling using ModFit LT.

G1(%)

G2(%)

S(%)

Apoptosis(%)

Control

72.45

3.21

24.33

0.00

OX25µM

31.31

28.39

40.30

6.75

OX25µM
+L-161,982 10µM

58.38

21.35

20.27

19.79
(n=3)
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Selective EP4 receptor agonist increased cell survival against oxaliplatin of chemonaïve cancer cells. EP4 receptor signaling has been shown important for chemo-naïve cancer
cell proliferation and survival upon stress (radiation, chemotherapy) (172,196) . To test the
effects of EP4 receptor signaling on oxaliplatin cytotoxicity to chemo-naïve cancer cells, we
treated two parental human adenocarcinoma cell lines, HT29 and RKO, with combinations of
oxaliplatin and the EP4 receptor selective agonist, L-902,688 for 72 hours. The addition of L902,688 significantly increased cell survival in both HT29 cells (IC50 value: 2.50µM compared
to 14.14µM; P<0.001) and RKO cells (IC50 value: 1.47µM compared to 5.86µM; P<0.001)
compared to oxaliplatin alone, measured by cell viability assay (Fig. 12A-B and Table 3). In
addition, co-treatment of L-902,688 and oxaliplatin reduced protein levels of cleaved PARP
cleavage in both cells lines, compared to oxaliplatin alone, indicating reduced apoptosis (Fig.
12C-D). These results further establish the significance of EP4 receptor signaling on oxaliplatin
sensitivity of chemo-naïve colon cancer cells, suggesting that EP4 could also be a potential target
to enhance oxaliplatin efficacy in initial CRC chemotherapy.
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Figure 12. Selective EP4 agonist reduced oxaliplatin sensitivity in HT29 parental cells.
Parental human colon cancer cell lines HT29 and RKO were either treated with different
concentrations of oxaliplatin alone (control) or co-treated with 1µM PGE2 or 1µM L-902,688 for
72h before cell staining or protein extraction. The levels of cell viability (A) HT29 and (B) RKO
were assessed using the MTT assay. Cytotoxicity rate was defined as the percentage of dead cells
In oxaliplatin treated cells compared to untreated cells. Levels of cleaved PARP and Bcl2/Bax
protein were detected in both (C) HT29 and (D) RKO cells using western blotting analysis.
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Table 3. 50% inhibitory concentrations of oxaliplatin in both cell lines were measured
using MTT assay.

Cell line

Control

PGE2 1µM

L-902,6881µM

HT29

2.51

7.36***

11.21***

RKO

1.46

1.39

5.860***
(n=4)
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2.4 DISCUSSION

The role of PGE2 in colorectal cancer development has been studied extensively for
decades. Several clinical trials have confirmed the chemo-preventive benefits of long-term
treatment with NSAIDs, such as aspirin or celecoxib (105) . Recent studies have shown
synergistic effects of COX-2 inhibition on improving the efficacy of chemotherapeutic agents (5FU and oxaliplatin) in both cell culture and preclinical colon cancer models (166,168,170) . For
example, short-term (up to 72 hours) treatment of COX-2 inhibitors (sulindac sulfide,
indomethacin, NS-398) has been shown to enhance efficacy of 5-FU and oxaliplatin on human
CRC cells (203,204) . The synergistic effect on oxaliplatin cytotoxicity is associated with
significantly reduced PGE2 level and increase expression of pro-apoptotic proteins (i.e.
Cytochrome C, caspase-3, caspase-9). Moreover, COX-2 may facilitate CRC chemo-resistance
by up-regulating the expression of ABC transporters and MDR1/P-gp, which mediates multidrug
resistance and enhance the drug removal from colon cancer cells (205,206) . These studies
introduced new aspects of NSAIDs application in CRC treatment. However, the use of COX-2
inhibitors have been associated with increased risk of cardiovascular events, such as myocardial
infarction and strokes, due to the suppression of cardio-protective PGI2 (prostacyclin) (207,208) .
Therefore, it is important to develop strategies that retain the anticancer benefits of COX-2
inhibition while avoiding the cardiovascular side effects. Our findings suggest that inhibition of
PGE2/EP4 receptor signaling may be a good adjuvant therapeutic strategy to enhance oxaliplatin
efficacy and circumvent oxaliplatin resistance, ultimately increase the survival of CRC patients.
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In consistent with its significant pro-tumorigenic functions, elevated level and
deregulated metabolism of PGE2 has been observed in colon cancer cell lines and patients,
compared to healthy controls (106,125,209) . In addition, previous studies have shown that
chronic oxaliplatin exposure induce multiple alterations in morphology and gene expression
patterns of human colorectal cancer cell, which may lead to COX-2 overexpression and
activation of eicosanoid signaling, resulting to aggravated tumor metastasis signaling, suggesting
COX-2 and PGE2 signaling may be involved in CRC oxaliplain resistance (199,210) . In the
present study, to mimic the development of oxaliplatin resistance of human CRC in vitro, we
used the well-established drug resistant cancer cell model, in which acquired resistance against
oxaliplatin was induced through long-term low dose oxaliplatin treatment to human colon cancer
cells. First we found that chronic treatment of oxaliplatin to human colon cancer cells resulted to
significantly reduced sensitivity to not only oxaliplatin, but also 5-FU, another first-line
chemotherapy, in spite of different mechanism of act by these drugs, indicating that there are
multiple mechanisms involved in the drug resistance in OXR cells. Further test on cell apoptotic
pathway and multidrug resistance mechanism revealed significant increases in both AKT
phosphorylation and Bcl-2/Bax ratio, but no difference in MDR1 expression, suggesting
deregulation of cell apoptotic pathway but not MDR in these cells.

Next, to examine the association between PGE2 metabolism and oxaliplatin resistance,
we measured secreted PGE2 level and key enzymes involved in PGE2 metabolism pathways. We
found a significant increase in the concentrations of PGE2 in the medium of HT29 OXR cells
compared to HT29 parental cells, which is likely due to both its increased synthesis and
decreased catabolism. The elevated PGE2 level is concomitant with up-regulation in AKT
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phosphorylation and Bcl-2/Bax ratio. Using siRNA-mediated PTGES knockdown, we found that
PGE2 suppression significantly reduces both AKT phosphorylation and cell survival against
oxaliplatin cytotoxicity. A possible explanation for the effect of PGE2 suppression on OXR cell
survival, is that the down-regulation of PGE2 synthesis reduced its signaling through EP2 or EP4
receptor, which is known to activate AKT pathway and exert anti-apoptotic and pro-survival
functions in colon cancer cells upon extracellular stress as PGE2 signaling has been shown in
association with cell survival pathway activation in colonic epithelial cells (173,211) . As recent
studies also associated PI3K/AKT pathway with chemoresistance in human colon cancer cells
(212,213) , suggesting that elevated PGE2 signaling may promote oxaliplatin resistance through
AKT-mediated mechanisms in OXR cells.

Although PGE2 suppression did somewhat sensitize OXR cells to oxaliplatin
cytotoxicity, this effect likely results from blocking the downstream signaling of all the EP
receptors, therefore lack specificity. EP receptors are known to each activate distinct downstream
signaling pathways and mediate different functions in cancer progression and treatment (214) .
Studies using mouse models with genetic ablation of selective EP receptor subtypes have
demonstrated the very different even conflicting roles played by EP receptors in colorectal
cancer pathogenesis (192) . For example, Sonoshita and colleagues determined that abrogation of
the EP2 decreases intestinal polyposis in ApcΔ716 mice, while genetic inactivation of EP1 and
EP3 receptor signaling has no effect on polyp formation (194) . However, in azoxymethane
(AOM)-induced colon cancer models, EP1 knockout mice developed fewer colonic neoplastic
leisons than wild-type mice, while EP3 knockout mice showed enhanced colon carcinogenesis
(195,215) . On the other hand, preclinical studies have shown that EP4 receptor promotes colon
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cell proliferation and survival, tumor metastasis, and suppressing antitumor immunity
(197,198,216) . Interestingly, EP4 receptor signaling has also been shown to transactivate EGF
receptor, thus establishing a crucial crosstalk between PGE2 and EGF signaling pathways that
promotes colorectal polyps growth (110) . These studies revealed the sophisticated cellular
functions of EP receptors, highlighting the importance of specifying the role of each EP receptor
in different models. To determine which EP receptor signaling mediates the pro-resistant
function of PGE2 in the OXR cells, we treated cells with selective antagonists against each EP
receptor. We found that blockade of EP4 receptor signaling by L-161,982 provided comparable
synergistic effects on oxaliplatin efficacy as PGE2 suppression, while inhibition of the other EP
receptors did not affect oxaliplatin resistance in OXR cells. Concomitant with less cell viability,
we also found increased cell death (higher sub-G1 proportion in cell cycle test), decreased AKT
phosphorylation and increased PARP cleavage in OXR cells co-treated with L-161,982 and
oxaliplatin, compared to treatment of oxaliplatin alone. These findings suggest that PGE2
promotes cellular survival specifically through EP4 signaling, which could be a mechanism of
oxaliplatin resistance in OXR cells.

In summary, we have demonstrated a critical role of PGE2/EP4 receptor signaling in
promoting oxaliplatin resistance in human colorectal cancer cells, possible via mechanisms that
involve cellular anti-apoptotic pathways. Combining with other studies on EP4 signaling in CRC
progression (196) , EP4 receptor and its signaling may serve as potent target for adjuvant
therapeutic strategy in human CRC treatment. Further studies are needed to explore the potential
of inhibiting EP4 or its downstream signaling using pharmaceutical molecules to increase
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oxaliplatin efficacy, circumvent oxaliplatin resistance, and ultimately increase the survival of
advanced CRC patients.
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CHAPTER 3

SIGNIFICANCE OF PGE2 SIGNALING IN MOLECULAR MECHANISMS INVOLVED
IN HUMAN CRC OXALIPLATIN RESISTANCE

3.1 INTRODUCTION

Oxaliplatin (1R, 2R-diaminocyclohexane oxalatoplatinum (II)) is a third generation
platinum compound and the only FDA-approved platinum-based first-line treatment for
advanced CRC patients. Different from other platinum-derivatives (i.e. cisplatin), oxaliplatin has
shown promising activity in CRC, with patient response rates of 12% to 24% as a single agent.
When combined with 5-FU as first-line therapy, the response rates increase to 60% or higher in
patients with previously untreated advanced colorectal cancer (217) .

The major mechanism of action by platinum drugs is that they bind to DNA covalently to
form platinum-DNA crosslinks, which cause DNA distortions, DNA damage response and
apoptosis pathway activation, therefore leading to cell death. However, cancer cells develop
various mechanisms, including loss of DNA mismatch repair, apoptosis pathway inactivation,
survival signaling enhancement, and increase of drug export mediated by MDR transporter, to
escape platinum-induced cell death and acquire drug resistance (147) . Due to its different
mechanisms of act, oxaliplatin is able to circumvent the intrinsic resistance mechanism and show
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efficacy during the initial treatment for colorectal tumors. However, almost all advanced CRC
patients develop acquired resistance after exposure to oxaliplatin for 6 months and eventually get
tumor metastases (218) . The molecular aspects of oxaliplatin resistance have been shown
different from drug resistance against other platinum-based compounds and remain unclear yet
(219) . To enhance oxaliplatin efficacy and overcome the acquired resistance against oxaliplatin,
it is very important to gain better understanding on the molecular mechanisms of CRC
oxaliplatin resistance, for novel target discovery or adjuvant therapy development.

It has been shown that besides the conventional chemo-resistance mechanisms, cancer
cells may take advantage of other strategies to escape the cytotoxic effect by chemotherapeutic
agents and acquire resistance (152,220) . Recently, cancer stem cells (CSC) have gained intense
interests for not only being crucial tumor initialing cells (TICs) in tumor progression, but also
key players in chemo-resistance of different malignancies (160,165) . CSCs are known as a
subpopulation of cancer cells in tumor mass, which maintain stem cell like properties. Besides
the intrinsic properties like slow proliferation, which already makes CSCs less sensitive to most
chemotherapy that targets fast-proliferating cells, CSCs haven been shown to pick up several
other mechanisms including MDR (through overexpression of ABC transporters) and hyperactivation of anti-apoptotic pathways (160,221) . After the initial response (tumor regression) to
chemotherapy, these resistant CSCs are responsible for driving tumor growth and tumor replase,
eventually lead to cancer related deaths. By generating chronic oxaliplatin resistant colon cancer
cells in vitro, Lee Ellis group have shown that long-term exposure to low concentration of
oxaliplatin could induce acquired drug resistance in human CRC cells, concomitant with
enrichment of CSC like subpopulation and phenotypic changes consistent with EMT, suggesting
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CSC may be involved in oxaliplatin resistance of human CRC (199,220) . Interestingly, in a very
recent study, Kurtova and colleagues associated PGE2 with chemoresistance through regulation
of CSC subpopulation for the first time (165) . They found that through blockade of PGE2
signaling using neutralizing antibody or celecoxib, they were able to abolish the CSC
repopulation and attenuate tumor recurrence in xenograft model of chemo-resistant bladder
cancer. These intriguing findings reveal a novel chemo-resistant mechanism mediated by PGE2
possibly through CSC regulation.

On the other hand, modulation of oxidative stress has been shown as the key mechanism
involved in cytotoxicity. Many conventional chemotherapeutic drugs attack DNA in both
nucleus and mitochondria, where the most reactive oxygen species (ROS) is generated. The
damage in mitochondria DNA causes deregulation of mitotic enzyme expression and generates
high level of ROS, triggering the intrinsic cell apoptotic pathway, leading to cell death (222) .
Because proliferating cancer cells usually contains multiple genetic mutations and high oxidative
stress, they are more susceptible to DNA damage an intrinsic apoptosis induced by
pharmacologically generated ROS (223) . However, after long-term exposure to chemotherapy,
cancer cells develop strategies such as up-regulation of antioxidant capacity to get adapted to
intrinsic oxidative stress, therefore confer drug resistance (223,224) .

Recently, oxaliplatin has been shown to induce colon cancer cell death through
generating high level of ROS; regulation of ROS-related mechanisms could enhance oxaliplatin
sensitivity in human colorectal cancer cells, suggesting it as a potential target to circumventing
oxaliplatin resistance in human CRC (225,226) . A recent study by Gallick group showed that
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treatment of oxaliplatin acutely activates Src, through intracellular ROS-dependent mechanism.
Src is the nonreceptor protein tyrosine kinase that correlates with high disease stage and poorer
patient survival. They also found that in oxaliplatin resistant cells, Src is constitutively activated.
Inhibiting Src by tyrosine kinase inhibitor dasatinib enhances oxaliplatin efficacy in vitro and in
vivo, suggesting a potential oxaliplatin resistance mechanism in human colorectal cancer
mediated by ROS (227) . Recently, Mo and colleagues found that inhibition of PGE2/EP4
signaling using selective EP4 receptor antagonist L-161982 could significantly increase cellular
ROS level and inhibit myoblast proliferation in vitro, providing an association between EP4
receptor signaling with regulation of intracellular ROS metabolism, suggesting that PGE2/EP4
signaling may affect colorectal cancer cell sensitivity to oxaliplatin through modulation of
intracellular oxidative stress (228) .

Taken together, studies suggest that PGE2 signaling may be involved in both CSC and
ROS mediated drug resistance mechanism and promote oxaliplatin resistance in human CRC.
Here, we hypothesize that PGE2/EP4 signaling promotes human colon cancer cell survival
against oxaliplatin treatment via regulating CSC and ROS related mechanisms; selective
blockade of PGE2/EP4 signaling could modulate stem cell phenotype and oxidative stress in
human colon cancer cells and circumvent oxaliplatin resistance in human CRC. To address our
hypothesis, we conducted the following study to evaluate both CSC and ROS-related
mechanisms in human CRC using an established oxaliplatin resistant cell culture model as
described before. We assessed the phenotype of CSC subpopulations in both resistant and
parental cell lines, and determined the effect of PGE2 suppression or PGE2 signaling blockade on
the CSC tumorigenic properties using selective EP receptor antagonist. We also examined the
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intracellular ROS level in both cell lines and evaluated the effect of EP4 inhibition on OXR cell
survival and intracellular ROS metabolism, either as single treatment or combined with
oxaliplatin. The impact of antioxidants on cell survival was also tested. By identifying the
connection between PGE2/ EP4 signaling and the potential mechanisms involved in oxaliplatin
resistance, we provide strong evidence for EP4 as a potent target to tackle the problem of
oxaliplatin resistance in CRC treatment.
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3.2 MATERIALS AND METHODS

Materials. Human colon cancer cell line HT29 were obtained from the American Type Culture
Collection (ATCC, Manassas, VA). The HT29 Oxaliplatin-resistant (OXR) cell line was
generated as previously described (199) . Briefly, chemo-naïve HT29 cells were exposed to
increasing concentrations of oxaliplatin over a three-month time-frame, with the final
concentration maintained at 2µM. Cell culture media and serum were purchased from Life
Technologies (Carlsbad, CA). Oxaliplatin, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis,
MO). PGE2, EP receptor antagonist L-161,982 was purchased from Cayman Chemicals (Ann
Arbor, MI).

Cell Culture Conditions. Human cancer cell lines were cultured at 37°C in a humidified
atmosphere of 5% CO2 in MEM, supplemented with 10% fetal bovine serum (FBS), 1%
penicillin-streptomycin, L-Glutamine, MEM vitamin solution, sodium pyruvate and MEM nonessential amino acids. Oxaliplatin resistant cells were maintained in 2µM oxaliplatin, but were
cultured in oxaliplatin-free media at least 24 hours prior to experimentation. Cells were
confirmed to be free of Mycoplasma using Mycoplasma Detection Test (200) . All experiments
were performed at 70% cell confluence with no more than 20 cell passages. Results from all
studies were confirmed in at least three independent experiments.

Cell Viability Assay. Cell sensitivity to drugs was assessed using cholorimetric 3-(4,5Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described previously.
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Briefly, cells were seeded in 48-well plates overnight and treated with or without drugs. After 72
hours, 100µl MTT solution (Sigma) was added to each well and incubated for 1h at 37°C.
Medium was then aspired and 300µl DMSO was added. Colorimetric analysis was performed at
a wavelength of 570nm using a standard microplate reader. IC50 curves were generated with
GraphPad Prism (software version 5.0c) using variable slope model.

RNA Isolation and Reverse Transcription Polymerase Chain Reaction (RT-PCR). Total
RNA was isolated using the RNeasy Mini kit (Qiagen Inc.). cDNA was synthesized using
Superscript III according to the manufacturer’s protocol (Invitrogen) mRNA expression levels of
genes of interest were examined with iTaq Universal SYBR Green Supermix (Bio-Rad
Laboratories, Inc.) on the ABI-7500 platform (Applied Biosystems). The levels of RNA
expression were normalized to GAPDH. The primers used for PCR amplification were: 5’-CAA
GTT CAA GCA GCT CTA CCG-3’ and 5’-GCT CCT GCA ACT CCT CAA AG -3’ for
HOMX1; 5’- AAG AAA GGA TGG GAG GTG GT-3’ and 5’-CAG AAC AGA CTC GGC
AGG AT-3’ for NQO1; 5’-TTG CAA CCA ATT TGG ACA TC-3’ and 5’- GTT CTG CCC
ATT CAC CTC AC-3’ for GPX; 5’-CTG GGA GCT CTT CTG ACT GG-3’ and 3’-TGG TGC
CTC AGG TTG TTA AA-5’ for DUOX2; 5’-AGG CTG TAC CAG TGC AGG TC-3’ and 5’CAA TAG ACA CAT CGG CCA CA-3’ for SOD1; 5’-CGT CAC CGA GGA GAA GTA CC-3’
and 5’-TAG GGC TGA GGT TTG TCC AG-3’ for SOD2; 5’-AAA CCA GTG GAT CTG CCA
AC-3’ and 5’-ACG TAG CCG AAG AAA CCT CA-3’ for NFE2L2; 5’-ACA ACT TTG GTA
TCG TGG AAG G -3’ and 5’-CAG TGA GCT TCC CGT TCA G-3’ for GAPDH. For each
experiment, PCR amplifications with no cDNA were performed as negative controls. The levels
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of RNA expression were normalized to GAPDH. PCR products were analyzed on 2% agarose
gel with ethidium bromide (E-gel, Invitrogen), together with 1 kb plus DNA ladder (Invitrogen).

Sphere Formation Assay. Tumor sphere formation was evaluated as previously described with
modifications (229) . Briefly, 100 cells were cultured in a 96-well ultra-low attachment surface
plate (Corning Life Sciences) with serum-free DMEM/F12 medium containing B27 supplement,
20 ng/mL EGF and 20 ng/mL FGF (Invitrogen) for 7 days. The sphere numbers in each well
were quantified. After 5 days, cells were supplemented with fresh SCM for another 100µl/well.
The formation of spheres was evaluated day 1, 3, 5 post seeding by light microscopy and the
number of spheres was counted at day 7 as indicator of cell sphere forming ability.

Immunofluorescence. Drug treated or control tumor spheres were grown on 8 chamber glass
slide (BD Falcon) for 1 week and fixed in 4% paraformaldehyde for 15mins, followed by
permeabilization and blocking by 5% goat serum/0.3% Triton X-100 in 1xPBS for 1 hour at
room temperature followed by incubation with primary antibodies overnight at 4°C and
secondary antibodies for 1h at room temperature in the dark. Nuclei were counterstained with
4’,6-diamidino-2 phenylindole (DAPI). Tumor spheres were mounted on to glass slides and
visualized using an Olympus fluorescence microscope (Olympus Corp.).

ROS Detection. Cellular ROS levels were detected with H2DCFDA (Life Technologies)
staining as previously described with small changes (230) . Briefly, cells were treated with drugs
or vehicle control. After 48 hours, cells were washed twice with serum free media then incubated
with 2 µM H2DCFDA in 2% FBS media at 37°C for 30mins. Following incubation, cells were
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washed twice with serum free media twice, trypsinized and collected for flow cytometry
analysis. None staining group as negative control and cells treated 2 hours treatment of 0.03%
H2O2 served as positive control. The levels of ROS in tested groups are measured by the
percentage of H2DCFA positive stained cells in total cell population.

Glutathione (GSH) Assay. To measure GSH level, cells were treated with drugs or vehicle
control for an 8-hour time-frame. Cells were collected using rubber policeman and cell numbers
were counted. Cell were then sonicated and centrifuged. Supernatants were deproteinated and
stored at -20°C until GSH measurement. Total GSH levels were then measured using a
commercial glutathione assay kit (Cayman Chemical, MI) according to manufacturer’s protocol.

Statistical Analysis. Date from all experiments was analyzed using the Student’s t test or twoway analysis of variance (ANOVA) when appropriate for analysis by GraphPad Prism (software
version 5.0c). For MTT assay, 50% inhibitory concentrations of oxaliplatin were calculated and
compared using Extra sum-of-squares F test. Results were considered as statistically significant
at a P value of less than 0.05. All statistical tests were two-sided.
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3.3 RESULTS

PGE2 level is associated with Cancer Stem Cell Enrichment in Oxaliplatin Resistant
Cells. One important mechanism of cancer chemoresistance is the enrichment of cancer stem
cells (CSC) in tumors (160,165) . Previous studies associated overexpression of stem cell
markers and expansion of CSC subpopulations with oxaliplatin resistance in human CRC
(199,220) . Consistent with these findings, in the present study, HT29 OXR cells showed
increased protein levels of colonic stem cell markers (CD133 and CD44) compared to parental
cells (Fig. 13A). Moreover, in tumor sphere formation assays, both HT29 PAR and OXR cells
formed viable tumor spheres with similar morphology. However, HT29 OXR cells demonstrated
a 2.5-fold increase (P<0.001) in tumor sphere formation over a 7-day time period, indicating
enhanced CSC capacity compared to HT29 parental cells (Fig. 13B).

As our previous work showed deregulated PGE2 metabolism in HT29 OXR cells, we’d
like to determine if PGE2 signaling is involved in the enhancement of tumor sphere-forming
ability and CSC subpopulation of OXR cells. PGE2 suppression via siRNA knockdown of
PTGES for 48 hours led to a significant reduction in the number of tumor spheres formed by the
resistant cells (~65% reduction; P<0.01), suggesting that PGE2 may directly contribute to the
tumorigenic behavior of OXR cells (Fig. 14B).
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Figure 13. Oxaliplatin resistant cells demonstrated enrichment of tumor initiating cell
subpopulaion. (A) HT29 PAR and OXR cells were cultured in drug-free medium for 72 hours
followed by protein extraction.Protein levels of stem cell marker CD44 and CD133 were
detected in both HT29 PAR and HT29 OXR cells using western blotting analysis. β-actin was
used for standard normalization. (B) HT29 PAR and OXR cells were plated in ultra-low
attachment 96 well plates (100 cells per well) for 1 week. The morphology of tumor spheres
formed by both cells were observed under microscope and (C) the numbers of viable tumor
sphere per well in each group were counted.
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Figure 14. PTGES knockdown significantly reduced in vitro tumor sphere formation by
H

HT29-OXR cells. HT29 OXR cells were treated with PTGES siRNA or non-targeting (NT)
siRNA for 48 hours followed by tumor sphere formation assay. After plated for 1week in ultralow attachment 96-well plates (100 cell per well), (A) the morphology of tumor spheres formed
by both cells were observed under microscope and (B) the numbers of viable tumor sphere per
well were counted.
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Blocking PGE2/EP4 receptor Signaling impaired Tumorsphere Forming Capacity of
Oxaliplatin Resistant Cells. To examine the significance of PGE2/EP4 signaling in CSC
subpopulations of OXR cells, the protein levels of both CD133 and CD44 were measured at 48
hours after EP4 inhibition. We found that treatment with L-161,982 reduced the protein levels of
both CD44 and CD133 in OXR cells (Fig. 15A). In tumor sphere assay, treatment with L161,982 significantly reduced the number of tumor spheres formed by HT29 OXR cells,
regardless of oxaliplatin treatment (Fig. 15B). Interestingly, treatment of oxaliplatin alone did
not affect the number of tumor spheres, but significantly reduced the size of tumor spheres
formed by OXR cells with or without the presence of L-161,982, suggesting that oxaliplatin
treatment could suppress the proliferation of CSC cells, but not the tumor initiation (Fig. 16). In
addition, blockade of EP4 signaling in HT29 OXR cells significantly reduced the expression of
stem cell markers (CD44 and CD133) within the tumor spheres (Fig. 17). These results suggest
that PGE2/EP4 signaling is critical for growth and abilities of CSC subpopulations in OXR cells,
which mediate a key mechanism for cell survival and repopulation against oxaliplatin
cytotoxicity.
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Figure 15. Selective EP4 blockade significantly reduced in vitro tumor sphere formation of
HT29-OXR cells. (A) HT29 PAR and OXR cells were cultured in oxaliplatin free medium for
24 hours, then treated with indicated combination of oxaliplatin and L-161,982 for 48 hours
followed by protein extraction. The protein level of stem cell markers CD44 and CD133 were
detected using Western Blot analysis. β-actin was used for standard normalization. (B) HT29
OXR cells were seeded in ultra-low attachment plate (100 cells per well) and treated with
indicated combination of oxaliplatin and L-161,982 for 1week. At day 7, numbers of viable
tumor sphere per well were counted.
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Figure 16. Morphology of tumor spheres formed by HT29 PAR and OXR cells with
combined treatment of oxaliplatin and L-161,982. HT29 PAR cells and OXR cells were
seeded in ultra-low attachment plate (100 cells per well) for 1week with indicated combination
of oxaliplatin and L-161,982. At day 1, 3, 5 post seeding, the morphology of tumor sphere
formed was observed under microscope.
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Figure 17. Selective EP4 blockade significantly reduced stem cell marker expression in
tumor sphere formed by HT29 PAR and OXR cells. HT29 PAR cells and HT29 OXR cells
were seeded in ultra-low attachment plate and treated as indicated for 1week. At day 7, the
expression levels of CD44 and CD133 in tumor sphere were detected using Immunofluorescence
Analysis.
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PGE2/EP4 receptor signaling is associated with deregulation of cellular oxidative
stress in oxaliplatin resistant cells. Recent studies have suggested that oxaliplatin activates
apoptotic pathways in colon cancer cells by inducing the accumulation of cellular reactive
oxygen species (ROS), while cancer cells may adapt oxidative stress modulation mechanism to
evade ROS-mediated cell death (230) . To determine whether a ROS-related mechanism is
involved in oxaliplatin resistance in OXR cells, we measured cellular ROS levels in both
parental HT29 and HT29 OXR cells using H2DCFDA staining followed by flow cytometry.
Compared to HT29 parental cells, oxaliplatin resistant cells maintained significantly lower
(~60%; P<0.001) basal levels of ROS, suggesting deregulation of ROS metabolism in OXR cells
(Fig. 18A). In addition, 48 hours of treatment with oxaliplatin (50µM) significantly increased
ROS in OXR cells. Interestingly, although treatment with L-161,982 (10µM) alone did not affect
ROS level, the addition of L-161,982 caused a further elevation in oxaliplatin-induced ROS
accumulation (~2.2-fold; P<0.0001) in HT29 OXR cells, indicating a strong association between
EP4 signaling and ROS metabolism in cancer cell oxaliplatin resistance (Fig. 18B).
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Figure 18. Blocking PGE2/EP4 signaling reduced cellular reactive oxygen species (ROS)
level in HT29 OXR cells. (A) HT29 PAR and OXR cells were cultured in oxaliplatin-free
medium for 72 hours before cell collection. The basal level of ROS in HT29 PAR and OXR cells
were detected with H2DCFDA staining and measured by flow cytometry analysis. (B) HT29
OXR cells were treated with vehicle control or combination of oxaliplatin(50µM) and L161,982(10µM) for 48 hours before cell collection. The cellular level of ROS were detected with
H2DCFDA staining and measured by flow cytometry analysis. Results are presented as the
percentage of fluorescence positive population.
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Blockade of EP4 signaling using L-161,982 sensitize HT29 OXR cells to oxaliplatin
cytotoxicity via reactive oxygen species (ROS) mediated mechanism. To determine the
significance of ROS mediated mechanism in the effect of EP4 selective inhibition on oxaliplatin
resistance, we treated HT29 OXR cells with combination of oxaliplatin, L-161,982 and an
antioxidant GSH precursor, N-acetyl cysteine (NAC). We found that the effects of L-161,982 on
maintaining higher ROS levels upon oxaliplatin treatment was reversed by addition of NAC (Fig.
19A). Consistent with the results on ROS levels, the addition of NAC to oxaliplatin caused a
synergistic effect with L-161,982 on oxaliplatin cytotoxicity as well, leading to increased cell
survival and oxaliplatin resistance in HT29 OXR cells (Fig. 19B).

To understand the underlying mechanism of ROS regulation by EP4 selective inhibition,
we measured the mRNA expression of enzymes involved in ROS metabolism and the cellular
level of the non-enzymatic ROS scavenger, Glutathione (GSH). We found that treatment of
oxaliplatin resulted in significant changes of GSH level within 48-hours post treatment, while L161,982 treatment reduced the levels of GSH (Fig. 20A). We also tested the expression of genes
encoding enzymes associated with GSH synthesis and utilization. Blockade of EP4 receptor for
48 hours significantly reduced the mRNA expression of the ROS-detoxifying enzyme,
glutathione peroxidase (GPX), and the cysteine provider, g-glutamyltraspeptidase (GGT) (~50%
reduction; P<0.00001 and ~70% reduction; P<0.0001, respectively) (Fig. 20 B-C). However, the
mRNA expression levels of other enzymes in ROS clearance were not affected by treatment of
L-161,982 (Fig. 21). Taken together, these results suggest that selective inhibition of EP4
signaling enables tumor cells to maintain higher levels of cytotoxic ROS through suppression of
GSH dependent ROS detoxification mechanisms.
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Figure 19. Synergistic effects of L-161,982 on oxaliplatin efficacy in HT29 OXR cells were
cellular reactive oxygen species (ROS) levels dependent. (A) HT29 OXR cells were treated
with indicated combination of oxaliplatin (50µM) and L-161,982 (10µM) and NAC (5mM) for
48 hours, followed with H2DCFDA staining. The cellular ROS level was measure by flow
cytometry analysis. (B) HT29 OXR cells were treated with indicated combination of oxaliplatin
and L-161,982 and NAC for 72 hours, followed by MTT assay. Cell viability rate was defined as
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Figure 20. Inhibition of EP4 signaling suppressed Glutathione (GSH) level and utilization
in HT29 OXR cells. HT29 OXR cells were treated with indicated combination of oxaliplatin
(50µM) and L-161,982 (10µM) for 48 hours, followed by supernatant collection and RNA
extraction. (A) The levels of cellular GSH at different time points were measured using
commercial GSH assay kit. (B-C) mRNA expression levels of GPX2 and GGT at 48 hours were
measured by RT-PCR analysis.
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Figure 21. Inhibition of EP4 signaling did not affect mRNA expression of GSHindependent enzymes in HT29 OXR cells. HT29 OXR cells were treated with indicated
combination of oxaliplatin (50µM) and L-161,982 (10µM) for 48 hours, followed by total RNA
extraction. The mRNA expression levels of SOD1, SOD2, HOMX1, NQO1 and NFE2L2 were
measured by RT-PCR analysis.
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Blockade of EP4 signaling using L-161,982 did not affect cellular ROS level in HT29
parental cells. Our previous results showed that EP4 inhibition did not affect oxaliplatin
cytotoxicity of parental cells (Fig. 10B). To determine whether EP4 inhibition affect cellular
ROS metabolism in HT29 parental cells, we treated HT29 cells with combination of oxaliplatin
and L-161,982. Addition of L-161,982 did not further increase ROS levels induced by oxaliplatin
alone in HT29 parental cells (Fig. 22A). However, combined treatment with oxaliplatin and the
EP4 receptor agonist, L-902,688, suppressed oxaliplatin-induced ROS up-regulation (Fig. 22B).
This data is in consistent with the results from cell viability experiments, in which treatment of
L-902,688 significantly increased cell survival in HT29 parental cells (IC50 value: 2.50µM
compared to 14.14µM; P<0.001) (Fig. 12A). Taken together, these results suggest that EP
receptor signaling is an important factor in oxidative stress regulation during cancer cell response
upon oxaliplatin treatment.
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Figure 22. Regulation of EP4 signaling affects oxidative stress level in HT29 cells. (A) HT29
cells were treated with indicated combination of oxaliplatin and L-161,982 for 48 hours followed
with H2DCFDA staining. The cellular ROS level was measure by flow cytometry analysis. (B)
HT29 cells were treated with indicated combination of oxaliplatin and L-902,688 for 48 hours
followed with H2DCFDA staining. The cellular ROS level was measure by flow cytometry
analysis.
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3.4 DISCUSSION

It has been shown that long term exposure of chemotherapeutic agents induce acquired
resistance in colon cancer cells, leading to tumor recurrence and metastases after initial response.
The common mechanisms involved in colon cancer chemoresistance include hyper-activation of
cell survival/anti-apoptotic pathways, deregulation of DNA repair pathways and multidrug
resistance (MDR) mechanisms (218,219) . Recently studies suggested that mechanism associated
with tumor initiation and metastases, such as enrichment of cancer stem cells and epithelial-tomesenchymal transition (EMT) of cancer cells in tumor mass, could also mediate the drug
resistance in human CRC (199) . On the other hand, the recent work by Wang and colleagues
suggested that PGE2/EP4 signaling could promote the expansion of CSC in colorectal cancer and
mediate tumor metastases, indicating that PGE2/EP4 signaling may also mediate drug resistance
through regulation CSC subpopulation of colon cancer cells (231) .

Previous work by Ellis lab demonstrated a significant enrichment of tumorigenic CSC
subpopulation in oxaliplatin resistant colon cancer cells, implying an association of CSC and
oxaliplatin resistance in HT29 OXR cells (220) . In the present study, we explored the potential
association between deregulated PGE2 synthesis and the capacity of cancer stem cells in resistant
cells. HT29 OXR cells demonstrated stronger tumorigenic ability by forming more tumor
spheres than parental cells, while PGE2 suppression by siRNA-mediated PTGES knockdown
significantly reduced the number of tumor spheres formed by OXR cells. These results suggest
that PGE2 (and possibly its downstream signaling) plays an important role in maintaining the
expansion of CSC subpopulation in HT29 OXR cells.
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To further determine the specific downstream signaling of PGE2 that is responsible for its
CSC promoting effect, we blocked EP4 recepotor signaling using selective antagonist L-161,982.
Treatment of L-161,982 led to a marked reduction in both tumor sphere formation and the
expression of the CSC markers, CD44 and CD133 in OXR cells. These findings may be due in
part to the down-regulation of AKT pathway, since studies have shown that EP4 signal through
PI3K-AKT pathway, and AKT signaling is critical for CSC proliferation or survival (232,233) .

Besides enrichment of cancer stem cells, another mechanism that cancer cells may utilize
to acquire chemoresistance is the upregulation of antioxidant capacity (223) . Oxidative stress is
a key mechanism involved in chemotherapy-induced cancer cell death. Due to vigorous
metabolism and multiple genetic mutations, cancer cells usually maintain higher level of ROS
generation of ROS compared to normal cells, making them more susceptible to DNA damage
and intrinsic apoptosis induced by pharmacologically generated ROS, providing an important
anticancer strategy (222,224) . However, consistent exposure to chemotherapy-induced oxidative
stress may exert selective pressure and induce adaption to intrinsic oxidative stress in the
survivor cells, therefore confer drug resistance (223) . Recently, oxaliplatin was shown to induce
colon cancer cell death through ROS generation (225) , suggesting that regulation of oxidative
stress may affect the sensitivity of human colon cancer cells to oxaliplatin cytotoxicity (226) .
Mo and colleagues found that inhibition of EP4 receptor signaling using L-161,982 significantly
increased cellular ROS level and inhibit cell proliferation in myoblast (228) . In the present
study, the HT29 OXR cells demonstrate significantly reduced basal level of ROS compared to
the parental cells, suggesting a possible adaption to oxidative stress induced by long-term
exposure of oxaliplatin. Although the treatment with L-161,982 alone did not affect the ROS
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level in cancer cells, blockade of EP4 receptor signaling by L-161,982 further boosted the
overproduction of ROS by oxaliplatin in OXR cells, but not parental cells, suggesting that the
synergistic effect of EP4 inhibition on oxaliplatin efficacy is possibly mediated through
modulation of oxidative stress. Furthermore, treatment of HT29 OXR cells with antioxidant
NAC reversed the effects of L-161,982 on both ROS level regulation and oxaliplatin
cytotoxicity. These results present suggest that PGE2/EP4 signaling plays an important role in
regulation of oxaliplatin induced oxidative stress in HT29 OXR cells, explaining the beneficial
effect of EP4 inhibition on oxaliplatin efficacy.

In cancer cells, ROS level is balanced by both ROS generation and scavenging (222) .
Our findings suggest that treatment of L-161,982 alone does not affect cellular ROS level;
However, EP4 inhibition could increase cellular ROS in the presence of oxaliplatin. These
findings not only confirmed that oxaliplatin could induced ROS generation as key mechanisms
of act, but also revealed an important role of PGE2/EP4 signaling in ROS scavenging, instead of
ROS generation. To further determine the ROS clearing mechanism regulated by EP4 signaling,
we tested the mRNA expression of enzymes involved in ROS clearance and the cellular level of
GSH, the critical non-enzymatic ROS scavenger in cancer cells (234) . Although we didn’t not
found significant difference in many ROS scavenging enzymes (including SOD enzymes,
HOMX1, NQO1, NFE2L2) upon the blockade of EP4 signaling, we did find that treatment of
OXR cells with L-161,982 suppressed the cellular level of GSH and reduced its utilization by
inhibiting the mRNA expression of GSH peroxidase (GPX), therefore reducing ROS elimination.
Taken together, these results suggest that treatment of oxaliplatin increase cellular level of ROS
in cancer cells, while in HT29 OXR cells, deregulated PGE2/EP4 signaling promotes the
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clearance of ROS through GSH mediated mechanisms. Inhibition of PGE2/EP4 signaling could
suppress GSH mediated ROS scavenging, therefore help maintain higher cellular level of ROS
and induce cell death.

In summary, we have demonstrated two important mechanisms involved in oxaliplatin
resistance of human colon cancer cells: CSC enrichment and modulation of oxidative stress.
More importantly, we discovered the direct association of PGE2/EP4 receptor signaling in both
mechanisms. Our results demonstrate direct evidence supporting the critical role of PGE2/EP4
signaling in maintaining enriched CSC subpopulation and regulating ROS-dependent mechanism
for oxaliplatin cytotoxicity in HT29 OXR cells, suggesting a critical role of PGE2/EP4 signaling
in promoting oxaliplatin resistance in human colorectal cancer cells. Combining with other
studies on EP4 signaling in CRC progression (196) , our findings provide the logical basis of
targeting PGE2/EP4 signaling for increasing oxaliplatin efficacy, circumventing oxaliplatin
resistance, and ultimately increase the survival of advanced CRC patients.
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CHAPTER 4

HISTOLOGICAL AND MOLECULAR ALTERATIONS OF ABERRANT CRYPT FOCI
IN THE INDUCIBLE BRAFV600E MUTATION CRC MOUSE MODEL

4.1 INTRODUCTION

Colorectal Cancer (CRC) is the third most common cancer and the fourth leading cause
of cancer death that accounts for approximately 609,000 deaths worldwide. In order to develop
effective preventive and therapeutic strategies and improve clinical outcomes for CRC patients,
numerous studies have been focusing on the molecular genetics of CRC tumorigenesis over the
past three decades (31) . In the “classic” model of colorectal tumorigenesis proposed by Fearon
and Vogelstein, the development of colorectal cancer follows the “adenoma-carcinoma”
sequence, driven by a relative limited number of genetic alterations including oncogene
activation and silencing of tumor-suppressor genes (235) . In this genetic model, the inactivation
of APC gene leads to the appearance of adenomatous polyps, the neoplastic precursor lesions in
colonic mucosa, therefore is regarded as the initiating step of human CRC. This step is followed
by further mutations in other genes such as TP53 and KRAS, leading to the development of large
adenoma and carcinoma. This stepwise pathway is regarded as the classic chromosomal
instability (CIN) pathway and account for approximately 70% of human CRC cases and have
been extensively studied for preventive (screening) and treatment purposes.
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Besides the CIN pathway, recent studies have indicated that approximately 30% of
colorectal carcinomas develop via an alternative pathway, the “serrated” pathway, named by the
histological feature of saw-toothed (serrated) crypts in the precursor colonic polyps (236) . This
concept of alternative pathways derived from the study on precancerous polyps. Previously, all
hyperplastic polyps are considered as benign lesions without malignant potential. In 1996,
Torlakovic and Snover described the histological difference between serrated polyps in serrated
polyposis syndrome (SPS) patients and the sporadic hyperplastic polyps, and observed serrated
adenomas and cancers developed in SPS patients to establish a strong association between
serrated polyps and serrated CRC (adenocarcinoma) for the first time (237) . Their studies
suggested that the hyperplastic polyps (now named as serrated polyps) are in fact a
heterogeneous group and some of the hyperplastic polyps are precancerous. The following
studies confirmed their findings and established the serrated pathway of CRC in which the
serrated polyps, instead of the traditional adenoma, represent the precursors of colon cancer.
According to the latest World Health Organization (WHO) classification, the serrated polyps are
categorized into three groups: the hyperplastic polyps (HPs), the sessile serrated adenoma (SSA)
and the traditional serrated adenoma (TSA) (238) . Although the malignant potential of these
polyps may vary, all three types of polyps share the same histologic feature of saw-toothed
crypts.

Distinct from the traditional colorectal tumors that harbor APC and TP53 mutations, the
serrated CRCs have been associated a distinct set of molecular features, such as MAPK pathway
activation, primarily via either BRAF or KRAS mutations, CpG island methylator phenotype
(CIMP) and DNA microsatellite instability (MSI) (236) . Based on these genetic characteristics,
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in 2007, Jass and colleagues (239) proposed the following molecular profiles to classify three
subtypes of serrated adenomas: (1) BRAF mutant, CIMP-high, MSI-high; (2) BRAF mutant,
CIMP-low, MSI-low and (3) KRAS mutant, CIMP-low, MSS/MSI-low (239) . The first two
groups share BRAF mutations and are more strongly linked to the serrated neoplasia pathway, in
which the SSAs arise.

BRAF is a serine/threonine protein kinase that plays critical role in EGFR mediated
MAPK pathway signaling in cancer cells. Activated by the upstream RTKs, the small GTPase
RAS, BRAF (and other isoforms including ARAF and CRAF) further activate MAPK signaling
to promote cell proliferation, growth and differentiation. BRAF is also found to mediate cell
migration, pro-survival and anti-apoptosis in cancer cells, therefore plays an important role in
tumor development of multiple malignancies (240) . In 2002, Rajagopalan and colleagues
discribed BRAF mutations in colon cancer patients for the first time, and also found that the
BRAF and KRAS mutations are mutually exclusive in human CRC (241) . Until now, oncogenic
mutations in the BRAF gene are found in approximately 10% CRC patients and have been
extensively studied for its clinical relevance. Compared to the APC or KRAS mutations, BRAF
mutations are often found enrich in proximal (right colon), serrated colorectal tumors and usually
associated with higher age, female gender and overall poor prognosis (28) . BRAF mutated colon
tumors have also displayed intrinsic resistance to BRAF inhibitors (i.e. vemurafenib) or antiEGFR treatments (242) . A better understanding of the biology associated with BRAF mutations
is imperative to develop effective strategies for the prevention and treatment of serrated pathway
CRC.
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Among over 30 single-site missense mutations that are mostly found within the kinase
domain of BRAF gene, a T1799A transversion, which causes Glu for Val substitution that
encodes constitutive active BRAFV600E accounts for 90% of BRAF mutations in human cancers
including melanoma and CRC (28,243) . BRAFV600E mutations have been found in over 80%
serrated carcinomas and 62% of micro vesicular hyperplastic polyps (MVHPs), leading to the
hypothesis that BRAFV600E mutation is a driver of serrated pathway and BRAF mutated HPs may
be the precursors of serrated CRC (242) . In 2013, Rad and colleagues (244) demonstrated that
BRAFV600E mutation could initiate serrated pathway of intestinal tumorigenesis using a
conditional BRAFV637E (the murine counterpart to human BRAFV600E) knock-in mice (Vil-Cre;
BrafLSL-V637E mice). In this model, the Cre-induced expression of mutated BRAF in epithelia of
small and large intestine induced the development of generalized MSI-high serrated hyperplasia
in both SI and colon, with progressed to dysplasia at age of 10 months. Inactivation of p16
further promotes the development of advanced carcinoma in Vil-Cre; BrafLSL-V637E mice. These
results suggest that serrated pathway could be initiated by BRAF mutation, yet requires tumor
suppressor inactivation for advanced CRC progression.

The study by Rad and colleagues (244) established an initiating role for oncogenic
BRAF in serrated adenomas, but whether BRAFV600E mutation drives the development of preneoplastic lesions such as aberrant crypt foci (ACF) in the serrated pathway of CRC is still
unknown. In 2007, the Hans Clevers group (189) discovered the exclusive expression of Lgr5, a
Wnt target gene, in the intestinal stem cells (ISCs) at the base of intestinal crypts. To study the
potential role of the BRAFV600E mutation in colonic pre-neoplastic lesions and provide a valuable
tool for developing preventive and therapeutic strategies for sporadic serrated CRC, in the
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following study we generated a conditional BRAFV600E knock-in mouse target specifically to
ISCs in C57/B6 mice. We further assessed the impact of tissue-specific, conditional BRAFV600E
mutations on the histological and molecular features of the colonic mucosa. By characterizing
the pre-neoplastic lesions induced by mutated BRAF, we reveal the link between hyperplastic
ACF and neoplasia in the BRAF-mutant serrated pathway of CRC. Further studies may discover
potential biomarkers for evaluating malignant potentials of hyperplastic ACFs and preventing
serrated polyps malignant transformations.
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4.2 MATERIALS AND METHODS

Generation of LSL-Braf

V600E

Lgr5 mice). Both LSL-Braf

;Lgr5-EGFP-IRES-creERT2 compound mutant mice (Braf-

V600E

mice and Lgr5-EGFP-IRES-creERT2 mice on the C57BL/6

background were purchased from The Jackson Laboratory and the generation of the mouse lines
has been previously described (189,245) . To generate the compound mutant mice, male LSLBraf

V600E

mice were crossed with female Lgr5-EGFP-IRES-creERT2 mice. Genotyping was

done by tail biopsy. Mice were maintained in a temperature-controlled, light-cycles room and
allowed free access to drinking water and standard lab mouse chow in the animal facility of
University of Connecticut Health Center (UCHC). Animals were weighed monthly and checked
twice a week for signs of weight loss or abnormal behaviors. Animal experiments were
conducted with approval from the Institutional Animal Care and Use Committee (IACUC),
UCH.

Tamoxifen treatment. Sixty three-week-old male and female mice were separated and BrafLgr5 mice were randomly grouped for the following experiments. There are five male mice and
five female mice in each group. At 6 week of age, mice received two intraperitoneal (i.p.)
injections of either tamoxifen (Sigma-Aldrich; 200mg/kg body weight) or corn oil (0.2ml) within
a timeframe of 72 hours. Body weight was recorded monthly. Mice were sacrificed at 4 weeks, 8
weeks and 12 weeks after the last injection, respectively. Colons were harvested, flushed
immediately with ice-cold phosphate-buffered saline (PBS) and excised longitudinally.
Specimens were fixed-flat in 10% neutral formalin solution overnight and stored in 70% ethanol
for further analysis.
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Quantification of colonic lesions. Whole-mount fixed colon specimens were stained with 0.2%
methylene blue and the number of ACFs per field (20x) were counted under a dissecting
microscope. The criteria for ACF examination were described in previous studies (246,247) .
The extent of hyperplasia in the colon was evaluated by H&E staining.

Immunohistochemistry. Small intestine and colon tissues were Swiss-rolled, paraffinembedded and sectioned at 7-µm thickness. Tissue sections were de-paraffinized and incubated
with 1 to 3 % hydrogen peroxide for 20 min and blocked with 10% normal goat serum in TBST
for 1 hour at room temperature. Sections were then incubated overnight at 4°C with anti-Ki-67
(1:600; Cell Signaling) or anti-green fluorescence protein (GFP; 1:200; Cell Signaling) followed
by incubation with the anti-rabbit SignalStain Boost IHC Detection Reagent (HRP, Cell
Signaling) for 30 min at room temperature. Signal was detected using diaminobenzidine solution
(Vector Laboratories). Tissues were counterstainedwith hematoxylin. Images were captured
using QCapture PRO software (QImaging, Surrey, BC, Canada).

Statistical Analyses. Data from all experiments was analyzed using the Student’s t-test or twoway analysis of variance (ANOVA) when appropriate for analysis by GraphPad Prism (software
version 5.0c). Results were considered as statistically significant at a P-value of less than 0.05.
All statistical tests were two-sided.
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4.3 RESULTS

Oncogenic BRAFV600E mutation activates MAPK signal transduction in colonic
crypts. To determine the impact of an oncogenic BRAFV600E mutation alone on normal colonic
mucosa, we generated the Braf-Lgr5 mice, in which the mutant BRAF gene expression is
inducibly expressed only in cre-expressing Lgr5+ stem cells at the bottom of the intestinal
crypts. At six weeks of age, Cre expression was induced in mice via two i.p. injections of
tamoxifen (200mg/kg body weight in corn oil) within a timeframe of 72 hours. For control
group, mice were injected with corn oil. Mice were sacrificed at age of 10 weeks, 14 weeks or 18
weeks. The body weight was measured at the time of sacrifice and colons were collected for
further analysis (Fig. 23). Four weeks after last injection, mice that received tamoxifen (TAM
group) injections showed elevated protein levels of phosphor-Erk in colonic epithelium
compared to mice in control group, indicating activation of MAPK signaling through oncogenic
BRAFV600E expression (Fig. 24A). However, no significant difference in body weight was found
between TAM groups and control groups (Fig. 24B).
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Figure 23. Study Design. At 6 weeks of age, a total of 60 LSL-Braf

V600E

;Lgr5-EGFP-IRES-

creERT2 mice (30 male and 30 female )were randomized and placed into 6 groups. In
Tamoxifen groups (n=10 each group), mice received injection of tamoxifen (200mg/kg in
20mg/ml of corn oil, i.p.) twice in 72 hours, and sacrificed at 4weeks, 8 weeks and 12 weeks post
injection. In Control groups (n=10 each group), mice received injection of corn oil (0.2ml, i.p.)
twice in 72 hours, and sacrificed at 4weeks, 8 weeks and 12 weeks post injection.
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Figure 24. Oncogenic BRAFV600E expression increases phospho-Erk levels in colonic crypts.
At 6 weeks of age, Braf-Lgr5 mice were injected with either tamoxifen (200mg/kg) or vehicle
control (corn oil) twice in 72 hours. (A) At 10 weeks of age, mouse colonic samples were
collected and paraffin embedded. Phospho-Erk IHC staining (indicated by arrows) was
performed to assess the status of MAPK signal transduction. (B) Mouse body weight was
measured at 4 weeks, 8 weeks or 12 weeks after the last injection of tamoxifen (TAM) or vehicle
control (control).
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Oncogenic BRAFV600E expression significantly increases the number of colonic
ACFs in adult Braf-Lgr5 mice. To determine whether BRAFV600E mutation alone could initiate
colon tumorigenesis, colon tissues from mice treated with tamoxifen (or controls) were formalinfixed and colonic epithelium was examined morphologically using methylene blue staining
under a light microscope. Compared to the colonic samples from mice in the control group, mice
injected with tamoxifen exhibit significant higher numbers of enlarged and darker stained
aberrant crypts with slit-shaped luminal openings (Fig. 25). The criteria for characterizing ACF
has been described in our previous studies (246) . Importantly, mice sacrificed 3 months post
tamoxifen-induced BRAFV600E mutation (age of 18 weeks) showed an increase in the size of
ACFs compared to mice in the other TAM groups, suggesting that the development of ACF upon
oncogenic BRAFV600E expression may be time-dependent (Fig. 25A).
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Figure 25. Oncogenic BRAFV600E expression induces development of ACF in the colonic
epithelium. At 6 weeks of age, mice were injected twice with either tamoxifen (200mg/kg) or
vehicle control (corn oil). At 10, 14 and 18 weeks of age, mice were sacrificed and colons were
harvested and prepared for analysis as described under Material and Methods. (A) The
morphology of crypts within the colonic mucosa was observed under a dissecting microscope
using methylene blue staining. (B) The numbers of ACFs per field were counted in both controls
and tamoxifen-treated mice.
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Oncogenic BRAFV600E expression induces colon epithelium hyperplasia in Braf-Lgr5
mice. The expression of the BRAFV600E mutant gene in Lgr5+ cells led to sporadic crypt
hyperplasia within the colon epithelium of tamoxifen-treated mice, as shown by both H&E
staining and presence of the proliferation marker, Ki67. Histologically, affected crypts
demonstrated significant elongation without dysplasia, as well as widen luminal openings and
enrichment of goblet cells (Fig. 26). In addition, sections of tamoxifen treated mice contain
higher number of crypts per field than those of the control group. On the other hand, the active
proliferating cells are observed in both the bottom and upper half of affected crypts from the
TAM group, while in contrast, the cell proliferation is restricted within the base of the crypts in
sections from control mice (Fig. 27), suggesting increase in proliferation of colonic epithelial
cells upon BRAFV600E mutation.
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Figure 26. Oncogenic BRAFV600E expression induces colonic hyperplasia in Braf-Lgr5 mice.
At 6 weeks of age, mice were injected twice with either tamoxifen (200mg/kg) or vehicle control
(corn oil). At 10, 14 and 18 weeks of age, mice were sacrificed and colons were harvested and
prepared for analysis as described under Material and Methods Colonic hyperplasia was
observed TAM group but not control group by H&E staining of paraffin sections.
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Figure 27. Oncogenic BRAFV600E expression promotes proliferation of colonic epithelial
cells in Braf-Lgr5 mice. At 6 weeks of age, mice were injected twice with either tamoxifen
(200mg/kg) or vehicle control (corn oil). At 10, 14 and 18 weeks of age, mice were sacrificed
and colons were harvested and prepared for analysis as described under Material and Methods.
The proliferative cells in colonic crypts were visualized in both TAM and control mice by Ki67
IHC staining in paraffin sections.
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Oncogenic BRAFV600E expression causes a loss of intestinal stem cells. Since studies
have shown that Lgr5 is exclusively expressed in intestinal stem cells (ISC) in SI and colon (and
certain stem cells in other systems), expression of the BRAFV600E mutant gene is limited to ISCs
in our mouse model. To understand the potential effect of the BRAFV600E gene mutation on
affected ISCs and the hierarchy of affected crypts, we examined the number of colonic stem cells
in both TAM-treated and control mice using GFP staining (Fig. 28). Colon sections from mice
treated with tamoxifen exhibited significantly less GFP+ staining per field compared to the
control group, suggesting that activation of the BRAFV600E gene mutation and an subsequent
MAPK pathway activation, significantly decreased the number of Lgr5+ ISCs in mouse colon.
This interesting finding is in consistent with the recent discovery by Riemer and colleagues (248)
, who found that broad oncogenic BRAFV600K mutation rapidly induced the depletion of ISC pool
in B6 mice over 3-day time period.
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Figure 28. Oncogenic BRAFV600E expression causes a loss of Lgr5+ cells. At 6 weeks of age,
mice were injected twice with either tamoxifen (200mg/kg) or vehicle control (corn oil). At 10,
14 and 18 weeks of age, mice were sacrificed and colons were harvested and prepared for
analysis as described under Material and Methods. (A) The Lgr5+ intestinal stem cells in colonic
crypts were visualized in both TAM and control mice by GFP IHC staining. (B) The numbers of
crypts containing GFP+ cells per field were counted in both control group and tamoxifen group.
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4.4 DISCUSSION

The MAPK signaling pathway is an important mediator in colorectal tumorigenesis.
Oncogenic activation of several key modulators in MAPK pathway, including KRAS and BRAF,
has been found in human CRC patients. KRAS mutations are present in 50% of CRCs while
BRAF mutations are found in approximately 10% CRC cases. Interestingly, the presence of
KRAS/NRAS and BRAF mutations in human CRC is mutually exclusive, and has been associated
with very different molecular pathways of CRC development. KRAS mutant CRCs often develop
through the traditional “adenoma-carcinoma” pathway and also exhibit loss of APC and TP53
gene, while BRAF mutant CRCs often develop through the alternative pathway – the “serrated”
pathway and are associated with high degree of CpG island methylation (CIMP) and/or genome
instability (MSI), which is possibly because the BRAFV600E mutation, leads to hyper-methylation
of MLH1 gene promoter and defects the DNA mismatch repair pathway (249) .

In the past decade, clinical studies have classified the BRAF mutant CRC as a distinct
subtype with very unique clinical characteristics and clinical behavior (28) . BRAF-mutant
colorectal tumors are primarily located in the proximal colon (right colon) with a mucinous,
serrated and poorly differentiated histology. It is also shown that BARF mutations are more
prevalent in female patients and those of advanced age. Moreover, patients diagnosed with
BRAF-mutant CRC tend to have poorer prognosis and shorter overall survival time, compared to
those with a wild-type BRAF gene (10.4months vs 34.7 months) (28) . These findings suggest
that oncogenic BRAF mutations may be associated with the tumorigenesis and clinical outcome
of proximal, serrated CRCs.
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Recent advances in gene sequencing and genetic modification technologies have
facilitated the research on BRAF mutations in human CRC. It has been confirmed that BRAFV600E
mutation, which is an oncogenic T1799A transversion that encodes constitutively activated
BRAF protein, accounts for approximately 90% of BRAF mutantions in CRC. In 2013, Rad and
colleagues provide the first evidence that BRAFV600E mutation drives intestinal adenoma
development using an inducible BRAFV600E knock-in mouse model (244) . Through the broad
expression of BRAFV637E, the murine counterpart of human BRAFV600E, in epithelia of small
intestine and colon, they showed BRAFV637E mutation could initiate the formation of serrated
colorectal tumor, which could be facilitated to generate an advanced carcinoma by further loss of
the tumor suppressor gene, p16. However, BRAFV600E mutations in all intestinal epithelial cells
lack translational relevance to the clinical development of serrated CRC in humans, which often
develops through somatically acquired sporadic mutations.

In our study, we cross the LSL-BRAFV600E mutant mice with Lgr5-EGFP-IRES-creERT2
mice and generate a mouse model in which the BRAF mutation can only be induced in Lgr5+
cells. Lgr5 has been found exclusively expressed in the ISCs at the base of intestinal crypts,
which leads to the wide usage of Lgr5 as imperative ISC marker in numerous stem cell studies
(189) . In 2007, Hans Clevers and colleagues generated the first Lgr5 -positive cell specific LacZ
expressing mouse model using inducible Cre gene expression system (Lgr5-EGFP-IREScreERT2) to identify and trace the lineage of the Lgr5 expressing ISCs. In our study, by crossing
these Lgr5 mice with LSL-BRAFV600E mice (245) , we generated the Lgr5-driven BRAF mutation
(Lgr5-BRAF) mouse line to induce the expression of mutant BRAF using tamoxifen-mediated
Cre expression and activate the MAPK signaling in affected crypts. Instead of adenoma
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development induced by germline BRAF mutation, we observed the generation of numerous
colonic ACFs induced by BRAF activation in Lgr5+ ISCs at different time points (4 weeks, 8
weeks and 12 weeks) after tamoxifen injections. Based on the histology test (H&E staining), we
also observed sporadic hyperplasia of colonic epithelium, which is characterized by elongated
crypt length, widen crypt openings and loss of goblet cell differentiation with more proliferative
cell (Ki67+ staining) towards the upper side of crypts. Clearly, our results suggest that sporadic
BRAFV600E mutation along in ISCs can initiate the hyperplasia in colon mucosa. However, we
didn’t observe dysplasia (characterized by loss of polarity, dark, elongated nuclei) in our tissue
sections. According to the findings from other studies, to achieve the malignant transformation
of pre-neoplastic lesions, a second step such as loss of tumor suppressor gene is needed.

Another interesting finding in our study is the observed loss of GFP+ (Lgr+) staining in
the colon of mice following activation of BRAFV600E expression. It is believed that most
hyperplastic lesions in colonic mucosa, including ACF and hyperplastic polyps, do not have
malignant potential. One hypothesis is that the activation of BRAFV600E, or activation of MAPK
signaling alone, could directly affect metabolism within affected cells and induce the elimination
of oncogene-altered crypts via the process of oncogene induced senescence, OIS. Recently, a
study by Riemer and colleagues (248)

showed that inducible, transgenic expression of

oncogenic BRAFV600E strongly activates MAPK signaling and induces the differentiation of ISCs
to transiently amplifying (TA) progenitor cells, thereby promoting the permanent differentiation
of ISCs and affected crypts in the mouse intestine. They also found that the activated BRAF
could modulate the expression of cell fate-associated genes in vitro, which might explain the
impact of BRAF mutations in vivo. However, because the BRAFV600E knock-in mouse was
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engineered in the embryonic stem cells and caused global intestinal hyperplasia, all mice were
sacrificed 4 days after its activation. Thus, it was not possible to observed the long-term effect of
a BRAF mutation on colonic epithelium in vivo. In our study, we were able to maintain the mice
for up to 3 months after induction (or even longer) and observed the loss of Lgr5+ cells (in which
the BRAFV600E gene was expressed). Our results are consistent with Riemer’s findings and could
serve as evidence for BRAF/MAPK signaling activation-induced loss of ISCs in mouse intestine.

In summary, we have established a stem cell-specific, inducible BRAFV600E knock-in
mouse model and provide preliminary evidence for the promotional effect of BRAFV600E
mutation on early stages of colonic neoplasia in vivo. We also uncovered an effect of the
BRAFV600E mutation on cell fate of ISCs that have sustained BRAF activation. We believe that
these changes may explain the potential failure of most of these hyperplastic ACF to progress to
advanced neoplasia. Further investigation is needed to better define the molecular mechanisms of
the oncogenic BRAF mutation and its direct effects on ISCs to gain a better understanding of
how crypts evolve during early carcinogenesis. On the other hand, our study provides a valuable
model for further studies with a goal towards developing early preventive strategies for proximal
serrated CRC, thereby improving the outlook of affected patients.
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CHAPTER 5

SUMMARY AND CONCLUSIONS

During the clinical treatment of CRC, the development of acquired drug resistance in
tumors after long-term exposure to chemotherapeutic agents can significantly decrease the
response rate of CRC to chemotherapy, leading to tumor recurrence and eventually cancerrelated deaths (160) . In addition, acquired resistance suppresses the efficacy of conventional
chemotherapeutic reagents, such as 5-FU and oxaliplatin, and limits their clinical application. In
fact, almost 90% of advanced CRC patients develop acquired resistance to oxaliplatin after
approximately 6 months of treatment, which decreases the efficacy of oxaliplatin and eventually
leads to tumor metastases and patient death (199) .

Oxaliplatin is a third generation platinum-based drug. Different from other platinumbased drugs (i.e. cisplatin), oxaliplatin features the bidentate ligand in structure and act through
different mechanism (unknown) to achieve effective cytotoxicity on colorectal tumor, therefore
remains the only FDA-approved first-line platinum compound for CRC (202) . Although several
common mechanisms, including modulation of cell apoptosis, deregulation of DNA repair
pathways and multidrug resistance (MDR) mechanisms, have been shown as involved in
platinum derivative resistance, the key mechanisms of oxaliplatin remains unknown (219) .
Recently, several studies have demonstrated the synergistic effects of COX-2 inhibition on
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improving the efficacy of oxaliplatin in CRC cell culture and preclinical colon cancer models,
suggesting that COX-2 pathway might be involved in the mechanism of oxaliplatin resistance.

The main product of COX-2 pathway, the bioactive pro-inflammatory lipid PGE2, has
been extensively studied for its critical promoting effect on colorectal tumorigenesis in the past
three decades. The chemo-preventive benefits of drugs targeting PGE2, such as NSAIDs and
celecoxib, have been confirmed in several large-scale clinical trials (105) . Recently, PGE2 has
been directly associated with chemoresistance in bladder cancer and breast cancer in vivo and in
vitro (165,167) . Our findings have revealed the direct link between deregulation of PGE2
metabolism and oxaliplatin resistance in CRC, providing the first evidence of PGE2 being a
potent modulator of CRC chemoresistance. In addition, we screened the downstream GPCRs for
PGE2 and confirmed the PGE2/EP4 receptor signaling as the pathway mediating oxaliplatin
resistance. Since PGE2 affords various critical biological and physiological functions in human
body, small molecule antagonist could target EP4 receptor specifically to maintain the beneficial
effect on oxaliplatin efficacy while circumventing side effects in clinical use.

As we investigated the impact of EP4 inhibition on human CRC cells, we found that
oxaliplatin resistant cells showed increased sensitivity to oxaliplatin upon EP4 blockade, while
oxaliplatin cytotoxicity on parental cells was not affected by EP4 inhibition. To further
understand the molecular mechanisms of “EP4 addiction” in these resistant cells, we evaluated
several mechanisms recently shown to be involved in CRC chemoresistance, including cancer
stem cells and modulation of oxidative stress. We found that both mechanisms have been
deregulated in favor of oxaliplatin resistance in our HT29 OXR cells, while inhibition of EP4
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signaling was able to reverse the de-regulation and suppress oxaliplatin resistance. For example,
EP4 blockade significantly reduced the expression of CSC markers CD44 and CD133 in OXR
cells and induced the decrease of tumor sphere formation by CSC subpopulation in OXR cells.
On the other hand, ROS-mediated cell apoptosis has been shown as key mechanism of
oxaliplatin cytotoxicity. We showed that inhibition of EP4 significantly reduced the cellular level
and utility of GSH, therefore reduced the clearance of ROS in HT29 OXR cells and induce cell
death. It is worth mentioning that the increase in GSH has been shown as a major contributing
factor to drug resistance in several malignancies, including ovarian cancer, prostate cancer and
melanoma, and GSH depletion has been tested as adjuvant therapy in several clinical trials (234)
. Our findings suggest that GSH also plays an important role in mediating oxaliplatin resistance
in human CRC. Further studies are needed to decipher the molecular mechanism of GSH
regulation by EP4 signaling and assess the effect of EP4 selective antagonist on oxaliplatin
resistance in preclinical models and clinical trials.

For decades, the development of human CRC has been assumed to follow the “adenoma
to carcinoma” sequence through the classic CIN pathway, and all hyperplastic the lesions in
colon mucosa, such including hyperplastic ACFs or polyps, are considered as benign and don’t
have malignant potential (93) . This opinion has been challenged by the emerging findings of
serrated CRC, which develops through a “serrated” pathway and exhibits distinct molecular and
histological features, including hyper-methylation of CpG islands, mutations in BRAF or KRAS
instead of APC gene, and “saw-tooth” like serrated crypts in polyps and adenomas (236) . In
addition, some hyperplastic ACFs/polyps have been found to carry oncogenic BRAF mutations
and exhibit serrated crypt phenotype, suggesting a strong association between these early lesions
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with serrated CRC. Nowadays, all ACFs have been regarded as biomarkers of increased CRC
risk and those with dysplastic features or acquired advanced genetic alterations are considered as
precursors of CRC with malignant potential. Especially, the ACFs at the proximal (right-sided)
colon are more frequently associated with proximal CRCs and could serve as potent target for
proximal CRC prevention (93) . However, till now a genetic engineered mouse model is yet to
generated for studying proximal premalignant lesions and developing preventive strategies for
proximal CRC.

Recent studies have suggested that BRAF, a key modulator of the MAPK signaling
pathway, is highly associated with colorectal tumorigenesis (240) . Oncogenic BRAF mutations
are present in approximately 10% CRC cases and have been found mutually exclusive with
KRAS mutations. Interestingly, BRAF mutations are extremely rare in left-sided colon cancer
and rectal cancers, instead they have been found primarily in proximal cancer, usually associated
with high degree of CpG island methylation (CIMP) and/or genome instability (MSI) (236) .
These proximal colon tumors usually develop through the “serrated” pathway and exhibit
mucinous histology with serrated and poorly differentiated colonic epithelium. Other clinical
studies also associate BRAF mutant CRC patients with older age, female gender and poorer
prognosis compared to those with wild-type BRAF gene (239) . These findings suggest that
oncogenic BRAF mutations might serve as a driver during early tumorigenesis of proximal CRC
and affect the prognosis of proximal CRC patients.

Recent studies have shown that broad expression of oncogenic BRAFV600E in intestinal
epithelial cells could initiate tumorigenesis and form serrated adenomas in mouse model (244) .
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To mimic the sporadic development of BRAF mutant CRC and study the impact of BRAFV600E
mutations on early tumorigenesis of proximal CRC, we generate the LSL-BRAFV600E; Lgr5EGFP-IRES-creERT2 mice, a novel GEMM in which oncogenic BRAFV600E mutation is
inducible in Lgr5+ ISCs at the crypt base in small intestine and colon, via tamoxifen-induced cre
expression. We found that expression of Mutant BRAFV600E promotes the development of
generalized hyperplastic ACFs in large intestine. The hyperplasia in colon epithelium was further
confirmed by epithelial cell hyper-proliferation throughout the affect colonic crypts indicated by
Ki67+ staining. However, we didn’t observe formation of adenoma or dysplasia in BRAF mutant
mouse colon. As previous studies have shown that the generation of advanced malignant lesions
requires further genetic alterations such as loss of TP53 or p16, it is possible that additional
silencing of tumor suppressor genes are needed to get dysplasia ACFs or SSAs. Interestingly, we
also found that expression of BRAFV600E and activation of MAPK signaling is associated with
decreases in Lgr5+ ISCs in BRAF mutant mouse. This finding is in consistent with the recent
discovery by Riemer and colleagues, who found that inducible expression of oncogenic
BRAFV600E for 4 days could activate MAPK pathway and promotes the differentiation of ISCs in
mouse intestine, therefore shrink the ISC pool during serrated tumor progression (250) . This
effect of mutant BRAF could be antagonized by β–catenin signaling, which has been shown to
encourage ISC identity. Our results confirmed the impact of BRAF mutation on the cell fate of
ISCs; however, by the end of 3 months post BRAF activation, we still observed plenty of Lgr5+
ISCs in BRAF mutant mice. Further investigations are required to understand the molecular
mechanisms underlying the maintenance of these BRAF mutant ISCs and discover potential
targets to prevent the transformation from hyperplastic polyps to SSAs during serrated CRC
progression, therefore improve the prognosis of affected patients.
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